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Abstract 
 
Even though platelets are the smallest cells in circulating blood, they play an integral 
role in blood clotting where they are activated, adhere to the vessel wall, and 
contribute to hemostasis. But over the years it was discovered that those anucleate 
cells have more extended functions. They organize their cellular vitality similar to 
nucleated cells and have an active protein metabolism performing protein de novo 
synthesis as well as protein degradation. One of the main degradation systems in 
cells is the proteasome. Besides protein quality control, the proteasome is involved in 
important cellular processes like cell survival, transcription, development, selective 
elimination of abnormal proteins and antigen processing.  
A dysregulation of this multicatalytic protein complex leads to various disease 
developments. Proteasome inhibitors, for instance, have been studied for treating 
cancer. Platelets like nucleated cells contain a proteasome. However, the impact of 
the proteasome on platelet functions remains poorly investigated until today. A better 
knowledge of signaling pathways in platelets aids in understanding how alterations in 
proteasome functions affect platelet-mediated processes and diseases.  
 
This study confirms the existence of a functional proteasome in human platelets and 
illustrates an important role in platelet biology, as well as sepsis. 
With this study the role of the proteasome in anucleate platelets is demonstrated in 
more detail and a signaling pathway regulating its activity was observed. Here, the 
proteasome in platelets is linked to platelet aggregation. First, proteasome inhibitors 
epoxomicin and bortezomib reduce ADP- and collagen-induced aggregation. 
Furthermore, the 26S chymotrypsin-like activity of the proteasome is enhanced when 
platelets are incubated with the platelet agonist collagen. Additionally, cytoskeletal 
proteins Filamin A and Talin-1, which are crucial for platelet activation, were identified 
as proteasome substrates and increased cleavage of these proteins occurs with 
proteasome activation.  
To investigate possible mechanisms of regulating the proteasome, the signaling 
pathway related to NFκB was analyzed under platelet agonist treatment. The NFκB 
pathway, that mediates aggregation, is initiated when platelets are treated with 
collagen and the inhibitory protein of NFκB, IκBα, is degraded in collagen-stimulated 
platelets. More interestingly, NFκB inhibitors prevent collagen-stimulated 
enhancement of the proteasome activity. In return the connection of the proteasome 
and the NFκB pathway is further demonstrated as NFκB inhibitors restrict cleavage 
of the proteasome substrate Talin-1. These results propose a novel pathway that 
involves the proteasome and that is in return connected with non-genomic functions 
of NFκB in regulating platelet aggregation. 
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In a second part this work shows for the first time that mitochondrial membrane 
depolarization in platelets correlates with the disease course and disease severity in 
patients with sepsis. Additionally, during these studies increased proteasome activity 
was observed in sepsis patients compared to control patients and pathogenic 
bacteria intensified the 26S trypsin-like activity of human platelets. Therefore, 
molecular markers of platelet vitality may be valuable parameters to help evaluating 
the clinical outcome of sepsis patients. 
In summary, the study confirms the existence of a functional proteasome in human 
platelets, contributes to our understanding how the proteasome affects platelet 
functions such as aggregation and how this may be regulated on a molecular basis. 
Furthermore, it allows for new insights in the disease course of sepsis and identifies 
new molecular markers for assessing the disease severity and clinical outcome of 
sepsis patients.  
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1 Introduction 
 
1.1 Blood platelet: Crucial part of vascular integrity 
Platelets are the smallest cells in circulating blood with a diameter of 2-4µm [1, 2]. A 
human platelet count lies between 150.000 and 300.000 platelets per µl blood. They 
derive from megakaryocytes in the bone marrow and have a physiological lifetime of 
about 7-10 days [3]. Platelets do not have a nucleus and are referred to as anucleate 
cells. It is well studied that they play an important role in vessel and wound repair. 
Platelets prevent blood loss by forming thrombi. Under physiological conditions 
resting platelets circulate with the blood flow. They have a discoid shape and roll 
along the intact endothelium. Traumatic action on the vessel wall, such as a cut 
requires clot formation to stop bleeding. Platelets attach to the vascular lesion, 
adhere, and form a primary hemostatic thrombus while attracting more platelets. 
During adhesion platelets undergo shape change, spreading or rolling and activation. 
In a last step platelets aggregate with each other.  
 
1.1.1 Resting and activated platelets 
As for other cells, those anucleate cells have a cytoplasmic membrane with 
membrane proteins. The platelet plasma membrane expresses numerous integrated 
proteins that are receptors for soluble agonist (such as ADP, thrombin or 
thromboxane A2) or adhesion proteins (such as fibrinogen, collagen or von 
Willebrand factor) [4, 5]. The plateletal cytoskeleton is important to maintain the 
discoid shape of resting platelets and actively aids in the platelet shape change. The 
cytoskeleton consists mainly of actin (15-20% of total protein mass), microtubuli, and 
actin binding protein, myosin. Actin exists in a globular form, G-actin, and in a 
filament form, F-actin [6]. Upon activation when the intracellular calcium 
concentration reaches a specific threshold platelets undergo chape change and 
pseudopods are formed [7]. The platelet looses its discoid shape. Microtubuli enrich 
in the pseudopods and G-actin polymerizes to F-actin, which associates with other 
structural proteins. F-actin filaments have a connection to the cell organelles and 
reorganize them during this activation process. Well-known organelles of platelets 
are mitochondria, glycogen stores and the storage granules (dense granules, α-
granules, and lysosomes) [8]. The lysosomes are similar to other cells and contain 
hydrolytic enzymes. The granules are characteristic for platelets and store proteins 
and other substances that are important for platelet function. The dense granules 
contain compounds, such as ADP, ATP, Ca2+, and serotonin to promote aggregation 
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and α-granules carry proteins, such as P-selectin or fibrinogen that play differing 
roles in adhesion, aggregation, chemotaxis, proliferation and inflammation [9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Morphology of resting and activated platelets. Upper panel shows electron micrographs 
of a resting platelet and an activated platelet (x20000 and x10000 respectively). The lower panel 
pictures transmission electron micrographs of cross-sections of a resting and an activated platelet 
(x21000 and x30000 respectively) [4].  
 
1.1.2 Receptor pathways of platelet activation 
Platelets have a number of different transmembrane receptors that interact with its 
physiological agonist to induce activation. Amongst others many integrins (such as 
αIIbβ3, α2β1), G-protein-coupled seven transmembrane receptors (protease-
activated-receptor PAR-1 and PAR-4 thrombin receptors, P2Y1 and P2Y12 ADP 
receptors, TPa and TPb TxA2 receptors), proteins of the immunoglobulin superfamily 
(GPVI), and C-type lectin receptors (P-selectin) are found on platelets. 
These platelet adhesion receptors are well understood and even though they differ in 
their functions and signaling pathways they have some similarities. First, there is the 
agonist/platelet receptor interaction followed by signaling pathways that promote 
secretion. Then released substances induce various platelet responses and cause 
further platelet activation as well as recruitment of other circulating platelets. The so-
called integrin activation and outside-in signaling is started. In the following the main 
platelet receptors will be mentioned and Figure 2 gives a schematic representation of 
platelet adhesion and agonist receptors with their cellular pathways.  
 
Fibrinogen receptor, integrin αIIbβ3 
The most abundant and best-studied integrin in platelets is the αIIbβ3 (GPIIb/IIIa) 
integrin, the fibrinogen receptor. This receptor is inactive in resting platelets but upon 
Katharina Gründler  1 Introduction 
3 
 
platelet activation it undergoes conformational changes becoming able to bind 
soluble plasma fibrinogen [10]. The outside-in signaling involves calcium mobilization, 
phosphorylation of proteins, activation of the phosphoinositide metabolism and 
cytoskeletal reorganization [11]. The αIIbβ3 integrin mediates the bridging between 
two platelets where fibrinogen connects two αIIbβ3 integrins with eachother. Integrin 
αIIbβ3 is the main adhesion molecule in platelet aggregation.  
 
Thrombin (PAR) receptors 
PAR receptors mediate platelet response to thrombin. PAR receptors are G-protein 
coupled receptors and on human platelets PAR-1 and PAR-4 are found. Both trigger 
PLC activation, Ca2+ mobilization, and PKC activation [12]. Thrombin stimulation 
results in platelet activation, shape change and the release of granules. PAR-1 and 
PAR-4 have different kinetics; to induce PAR-4 mediated signaling a higher thrombin 
concentration is necessary [13].  
Thrombin as a protease acts on PAR receptors by binding to the extracellular domain 
and cleaving the receptor to form a new peptide ligand. Thrombin unmasks a specific 
ligand for the PAR receptors that then activates the receptor and induces 
transmembrane signaling [14].  
 
ADP receptors, P2Y receptors 
The agonist ADP binds to the ADP receptors P2Y1 and P2Y12, G-protein-coupled 
receptors [15, 16]. One receptor is coupled to Gαq G protein (P2Y1) and the other is 
coupled to Gαi (P2Y12). While P2Y1 stimulates PLCβ enhancing cytosolic Ca2+, that 
activates PKC and leads to platelet shape change [15], P2Y12, which is coupled to 
Gαi, goes another way. P2Y12 inhibits the adenylate cyclase and activates 
phosphatidylinositol 3-kinase (PI3K) [17]. Activated PI3K promotes then AKT and 
Rap1B activation [18]. This stimulation of Gαq and Gαi signaling pathways is 
necessary for a fibrinogen receptor activation, thus for platelet-platelet adhesion.  
Antiplatelet agents are effective in the treatment of arterial thrombosis. Those agents 
target different critical steps in thrombogenesis. But important antiplatelet agents are 
clopidogrel and prasugrel that target the ADP receptor P2Y12 [19].  
 
Thromboxane receptors 
Thromboxane A2 (TXA2) is a prostaglandin with potent platelet activating 
characteristics. Thromboxane receptors (TPs) induce a cytosolic Ca2+ enhancement 
and an influx of extracellular Ca2+, which activates the PLA2 resulting in arachidonic 
acid (AA) hydrolysis from membrane phopholipids and converting it into TXA2 [20]. 
TXA2 then acts on its receptor again [21]. Because TPs are coupled to Gαq but not 
Gαi family members they require a secretion of ADP for platelet aggregation. ADP 
inhibits the adenylate cyclase mediated through the P2Y12 that is coupled to Gαi.  
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Collagen receptors, integrin α2β1 and GPVI 
Following injury to the vascular wall, collagen is exposed on which amongst others 
platelets adhere rapidly. Collagen I and III are considered the most important 
collagens at the injured cite to induce platelet adhesion and platelets have many 
collagen receptors. Most collagen receptors are known but there might exist more 
due to the fact that there are receptors directly and indirectly binding collagen [22]. 
An indirect collagen receptor is the GPIb complex (CD42c) that interacts with von 
Willebrand factor, which then binds to various collagens in the subendothelium. The 
integrin α2β1 and the Ig superfamily receptor GPVI are the major direct collagen 
receptors [22].  
Integrin α2β1 is known as GPIa/IIa or CD49b/CD29. As all integrins, α2β1 is a large 
glycoprotein with extracellular domains, transmembrane domains and cytoplasmic 
domains. On resting platelets α2β1 is expressed in a low-affinity state (similar to the 
inactive state of the fibrinogen receptor) and the affinity of α2β1 to soluble collagen 
increases on platelet stimulation [23]. Thus integrin α2β1 seems to require an earlier 
agonist-induced conformational change to bind to collagen [24]. Src and Syk family 
tyrosine kinases are activated by α2β1 leading to the activation of PLCγ2 and the 
formation of lamellipodia [25]. There is a complex crosstalk between α2β1 (collagen 
receptor) and αIIbβb3 (fibrinogen receptor); α2β1 promotes the activation of αIIbβb3 and 
as a consequence induces fibrinogen binding to adherent platelets [26]. 
The collagen receptor GPVI is connected to the immunoreceptor tyrosine-based 
activation motif (ITAM) and its cytoplasmic domain is bound to the Src family kinases 
Fyn and Lyn [27, 28]. When collagen binds to GPVI, ITAM is tyrosine phosphorylated 
by those Src family kinases and initiates a complex signaling cascade activating a 
series of adapter and effector proteins [29]. The main enzyme activated is PLCγ2 that 
leads to the second messengers 1,2-diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3). IP3 in turn triggers intracellular Ca2+ mobilization, protein 
phosphorylation and AA release. AA drives aggregation and secretion of TXA2 and 
ADP [30].  
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Figure 2: Schematic model of main platelet receptors and their cellular pathways [31]. The left 
panel shows adhesion as well as agonist receptors and the right panel shows major cellular pathways 
triggered by platelet agonists. The fibrinogen, thrombin, ADP, thromboxane A2 and collagen receptors 
are discussed above. 
 
1.1.3 Aggregation 
While platelets adhere they not only undergo activation but also aggregate. 
Aggregation is defined as the process of coadhesion of two platelets. Primary and 
secondary aggregation are told apart. Primary aggregation is reversible and platelets 
are only loosely connected by fibrinogen after activation. When they release their 
granule components secondary aggregation starts, the binding of fibrinogen 
becomes stronger and this process is irreversible [32]. Without fibrinogen or Ca2+ 
aggregation is not possible. Those two components are also stored in platelet 
granules to achieve high concentrations of both of them in a thrombus.  
The measurement of aggregation is the most common method for the diagnosis of 
platelet function. Platelet aggregation can be detected amongst others by light 
transmission aggregometry, LTA, also called Born aggregometry or through 
impedance aggregometry, IA [33]. During IA electrical impedance in whole blood is 
measured with two sensor electrodes. When platelets aggregate they adhere on the 
metal wire and increase electrical resistance. During LTA light transmission is 
detected by a photocell that sits behind a cuvette. While platelets aggregate, less 
light is absorbed and the transmission increases. The aggregation curve measured 
by LTA, Born aggregometry, can follow a monophasic or biphasic aggregation 
depending on the agonist. After ADP stimulation platelets undergo a shape change 
that is recognized by a decrease in light transmission, followed by the primary 
aggregation (reversible) where the curve rises, and then the curve can either fall 
(deaggregation) or goes through a plateau into the second phase of aggregation 
(irreversible). Platelets activated with collagen show a delayed and longer decrease 
in light transmission (shape change) and have a monophasic curve.  
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1.1.4 Platelets in vascular inflammation and diseases 
Next to inherited platelet disorders that affect, e.g., platelet adhesion, activation or 
secretion, platelets play a crucial role in the involvement of various diseases.  
Since platelets play a central role in stopping bleeding by clot formation they have a 
major part in pathophysiological thrombus formation as well. During atherosclerosis 
an interaction among platelets, endothelial cells, and leukocytes establishes a 
localized inflammatory response that accelerates atherosclerosis, thrombus formation 
and might result in a heart attack or stroke. Platelets normally interact with the 
endothelium to maintain their physiological function and to enhance leukocyte 
recruitment to sites of inflammation but when those physiological responses are 
exaggerated at atherosclerosis sites pathogenesis of this disease is stimulated [34].  
Moreover, growing evidence shows that platelets contribute to cancer progression. 
Complex crosstalk between tumor cells and circulating platelets enhances tumor 
growth and platelet receptors as well as platelet agonist play a role in cancer 
metastasis [35]. 
Additionally, the exact role of platelets in sepsis with its underlying molecular 
mechanisms is still to be analyzed. But it is suggested that platelets promote 
inflammation during the early stages of infection thus helping prevent sepsis. 
Nevertheless, thrombocytopenia is a common finding in severe sepsis and it might 
result from platelets undergoing apoptosis [36, 37]. Although apoptotic proteolysis 
might contribute to thrombocytopenia in sepsis other mechanisms are involved. It is 
known that platelet activation and aggregation is regulated in sepsis through Toll-like 
receptors expressed by platelets and bacterial exotoxins [38]. Moreover, the role of 
patelet-leukocyte adhesion during sepsis coming from activated platelets needs to be 
analyzed. While activated platelets secrete key components of the coagulation and 
inflammatory cascade, there are only few studies on platelet function in sepsis. 
Thrombocytopenia in general is found during many diseases. It might be drug-
induced however it needs to be considered during the process of healing. 
 
1.2 Organization of cellular vitality and protein 
metabolism in platelets 
Platelets are known for their ability to stop bleeding and for many years that was 
thought to be their only function. But over the years platelets have shown more 
extended functions. They obsess many features that were believed, to be seen only 
in nucleated cells. It was discovered that those anucleate cells are not as simple as 
everyone believed. Those small particles are surprising. Platelets are able to migrate, 
proliferate, go into apoptosis, and present antigens. They even contain transcription 
factors and are able to perform protein de novo synthesis.  
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1.2.1 Migration and proliferation of platelets 
For a long time platelets were believed to be static cells that do not leave the site of 
adhesion, even though there was some evidence that platelets in vitro are able to 
move through a Boyden chamber [39]. Years later platelets were found to migrate in 
vivo and more detailed analysis demonstrated that platelets are able to migrate in a 
SDF-1-mediated fashion even through an endothelium [40-42]. Further evidence for 
platelet migration is published continuously [43-45]. 
Yet, more astonishingly in 2010 Schwertz et al. discovered that platelets are able to 
produce functional progeny. There seems to exist a cell division that does not require 
a nucleus. Platelets form new cell bodies that contain mitochondria and α–granules. 
Moreover the new fragments adhere and spread normally, express P-selectin and 
annexin V in the typical way after stimulation [46]. 
 
1.2.2 Regulation of apoptosis 
When apoptosis, programmed cell death, was observed it was exclusively assigned 
to nucleated cells [47]. However, apoptotic signs were discovered in platelets [48, 
49]. Numerous chemical agents such as the calcium ionophore A23187 trigger 
platelet apoptosis but also the platelet activator thrombin is able to induce apoptotic 
events in platelets [50, 51]. Moreover, the process of apoptosis might be induced 
without stimulants in platelets, under pathological high shear stress or long-term 
incubation of platelets under blood banking conditions [50, 52].  
While the intrinsic mitochondria-dependent pathway is well studied in anucleate 
platelets, the role of the extrinsic pathway remains unclear [53]. 
During apoptosis in platelets a depolarization of the mitochondrial membrane 
potential has been demonstrated. The mitochondrial membrane potential decreases 
in canine platelets after an estradiol treatment [54] or apoptotic stimulants A23187, 
thrombin or high shear stress induce a reduction of the mitochondrial membrane 
potential in human platelets [50, 51]. Degradation of the anti-apoptotic protein Bcl-xL 
after treating platelets with bacteria was shown and pro-apoptotic proteins Bax and 
Bak are higher expressed under, e.g., thrombin-induced plateletal apoptosis [36, 51]. 
Pro-apoptotic proteins also show higher expression in in vitro aged platelets [55]. 
Induction of activation of caspases -3, -8 and -9 was found in human platelets as well 
[56]. Other apoptotic markers, such as phosphatidylserine translocation to the outer 
leaflet of the plasmamembrane, and chytochrome c release were analyzed in 
platelets [50, 57]. Furthermore, platelet shrinkage, membrane blebbing and 
microparticle shedding, visible by microscopy, can be found in plateletal apoptosis 
[50, 55]. All those apoptotic markers in platelets are summarized in a model for 
apoptosis in platelets (Figure 3).  
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Figure 3: Model of apoptosis in platelets [53]. Shown are platelets with their apoptotic markers 
undergoing apoptosis when stimulated with chemical stimuli or high shear stress.  
 
1.2.3 Platelets: Antigen presenting cells 
A connection of platelets in processing and presenting antigens had long not been 
made. However, in 2012 Chapman et al. stated that platelets express MHC I (major 
histocompatibility complex class I) molecules and present antigens to naïve T cells. 
They not only measured antigen presenting molecules on platelets in different in 
vitro-incubations but also analyzed platelets isolated from infected and uninfected 
mice [58]. Additionally, it is known that platelets express many proteins or RNA 
transcripts, which are necessary for processing antigens and presenting them. 
Platelets contain the endoplasmatic reticulum and a Golgi, where peptides to be 
presented are processes and loaded on MHC I molecules. The proteasome that 
helps by cleaving peptides that are to be presented is found in platelets, as well as 
TAP (transporter associated with antigen processing), a protein that brings cytosolic 
peptides to the ER [59, 60]. Many more proteins (such as calnexin, calreticulin and 
Erp57) that facilitate correct folding of MHC I molecules and its association with β-
microglobulin, were detected in platelets [61, 62].  
Proteomic analysis of platelets has brought further evidence for the existence of MHC 
I molecules. The MHC I complex is found in α–granules of platelets [60] and the 
global proteome analysis from Klockenbusch et al. identified the MHC I maschinery 
as well [63]. Zufferey et al. provides a model of MHC I antigen-presenting pathway in 
human platelets with its identified proteins (Figure 4).  
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Figure 4: Schematic overview of the MHC I antigen-presenting pathway in human platelets. 
MHC I is loaded in the ER and brought to the plasma membrane over the Golgi in a secretory granule. 
Modified from Zufferey et al. [60]. 
 
1.2.4 Transcription factors in human platelets affect platelet 
functions 
Although platelets are anucleate, recent publications show that platelets express 
transcription factors. Transcription factors including the steroid/nuclear receptors [64], 
peroxisome proliferator activated receptor (PPAR) β/δ and γ [65, 66], the 
glucocorticoid receptor (GR) [67], retinoid X receptors (RXR) [68] and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB) were found in platelets [69, 
70] and they indeed influence platelet functions. For instance, the nuclear receptor 
estrogen β potentiates thrombin-stimulated platelet aggregation [71]. PPARγ prevents 
the release of TXB2 and ATP after thrombin stimulation [66]. The glucocorticoid 
receptor bound to its ligand prednisolone seems to inhibit platelet aggregation [67] 
and the retinoid X receptors inhibit platelet aggregation through Rac inhibition and 
prevention of Ca2+ release [68].  
Taken together, this suggests non-genomic functions of transcription factors in 
platelets. Also in erythrocytes, another anucleate cell type, transcription factors were 
found [72]. Thus, anucleate cells like platelets and erythrocytes seem to be the ideal 
human experimental model to study non-genomic functions of transcription factors. 
Since some transcription factors like nuclear receptors are already known to possess 
non-genomic functions in nucleated cells [73], it is not as surprising that they play a 
non-genomic role in platelets. But that other transcription factors might also have 
non-genomic functions is a whole new research field. Here I will focus on the 
transcription factor NFκB that had mostly been studied in nucleated cells and its 
genomic functions there are well known. Nevertheless, the recent identification of 
NFκB in anucleate platelets is fascinating and promises a better understanding of 
platelet biology.  
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NFκB signaling pathway 
The NFκB pathway has diverse functions and in accordance with this the NFκB 
transcription factor family consists of 5 members (p50, p52, p65, RelB and c-Rel) [74, 
75]. All of them contain a nuclear localization sequence (NLS) in their N-terminal 
domain and they are normally found in the cytoplasm associated to an inhibitory 
protein that masks their NLS [76]. The inhibitory proteins belong to the IκB family with 
its most common member IκBα. The NFκB transcription factor proteins can form 
homo- or heterodimers what again demonstrates the diverse function of this signaling 
pathway. NFκB bound to the inhibitory protein might be considered inactive. 
There are several NFκB activation pathways but the most frequent one is the 
canonical. This pathway is activated in response to various inflammatory stimuli. 
Hereby the IκB kinase (IKK) complex is activated and phosphorylates the inhibitory 
protein IκBα at Ser32 and Ser36. This phosphorylation results in a rapid 
ubiquitination and degradation of IκBα by the proteasome [76]. Then the so-called 
active NFκB dimer with its liberated NLS sequence translocates to the nucleus where 
it selectively activates the transcription of various genes mainly involved in 
inflammation. The left panel of Figure 5 pictures this pathway.  
As NFκB mainly activates inflammatory genes, it is found activated amongst others in 
rheumatoid arthritis, an inflammatory disease. In the joint tissue NFκB of resident 
macrophages provokes transcription of many pro-inflammatory cytokines and 
chemokines leading to a subsequent invasion of a large number of immune cells to 
the joint tissue. In an autocrine and paracrine manner cells are kept activated there 
[77].  
 
NFκB in platelets 
Over the last years evidence was regularly published that NFκB exists in anucleate 
platelets and exerts non-genomic functions. Already in 2002 Liu et al. showed the 
existence of some NFκB/IκB family members in human platelets and demonstrated a 
phosphorylation and degradation of IκB during platelet activation [69]. This was not 
as absurd because thrombin, a platelet activator, is able to induce the NFκB pathway 
in smooth muscle cells [78]. Malaver et al. analyzed further the functional significance 
of NFκB in human platelets. They confirmed the expression of p65, IκBα and its 
degradation. Moreover, they approached NFκB’s function, which seems to mediate 
platelet aggregation [70]. NFκB inhibitors restricted platelet spreading, impaired 
aggregation and reduced ATP release, TXB2 formation and P-selectin expression 
[70]. Just a little later further publications stating functional NFκB in platelets were 
published. Spinelli et al. used a different NFκB inhibitor and demonstrated reduced 
platelet spreading, as well as lamellapodia formation [79]. Gambaryan et al. 
described IKK activation after platelet activation in mice. However, they also showed 
an induction of aggregation by IKK inhibitors [80]. This seems as the exact opposite 
of findings from Malaver and Spinelli but it could just demonstrate the complexity of 
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the IKK complex, which is known to have multiple substrates (not only NFκB) in 
nucleated cells. The IKK complex might have multiple substrates in platelets as well 
[81]. 
Furthermore, additional evidence of NFκB’s existence and non-genomic function in 
platelets is given from year to year [82-86]. There was a study on a substance that 
inhibits NFκB-mediated platelet aggregation [83] and the IKK seems to possess a 
non-genomic function in platelet secretion [85]. 
Taken together, NFκB pathway members are present in platelets and seem to 
function in a novel non-genomic way. The right panel of Figure 5 summarizes these 
findings of NFκB in platelets.  
 
 
 
Figure 5: NFκB pathway in eukaryotic cells and its non-genomic functions in platelets. Left 
panel: Basic illustration of the canonical NFκB pathway in eukaryotic cells. ECM: extracellular matrix, 
ICF: intracellular fluid. Right panel: NFκB and its family members in platelets with possible non-
genomic functions demonstrating the complexity of the NFκB pathway. This illustration is based on 
publications until today [70, 79, 80, 85, 87]. 
 
1.2.5 Protein de novo synthesis and protein degradation in platelets 
Essential for nucleated cells is their ability to transcripe DNA to RNA and translate it 
in order to synthesize a protein. Platelets lack nuclei and as a consequence do not 
possess cellular DNA, but they have mitochondria with the mitochondrial genome 
[88, 89]. Nevertheless, they were considered incapable of regulating protein 
Katharina Gründler  1 Introduction 
12 
 
synthesis [90]. In the 1960s it was published that platelets can absorb amino acids 
and might synthesize proteins but only in 1998 it was shown that platelets build a 
specific protein upon stimulation [91, 92]. Since then many proteins found in the 
platelet profile were found to be de novo synthesized in platelets [93]. Translation 
does not require a nucleus and is encountered in platelets giving them an alternative 
route for gene control [94]. Also an evolving area of research is the synthesis of 
proteins during storage of platelet concentrates.  
More evidence for protein de novo synthesis in platelets is published every year. For 
instance, platelets indeed contain not only functional mRNA but also ribosomal RNAs 
and other protein components (such as Dicer or the spliceosome) to perform 
translation [93, 95].  
Hand in hand with protein synthesis goes protein degradation. To maintain protein 
homeostasis, cells balance protein synthesis with degradation. Protein degradation in 
nucleated cells is well studied and is performed by two main pathways, the lysosomal 
and the ubiquitin proteasome system. Our current understanding of degradation 
pathways in platelets is not as detailed. Platelets contain the cysteine protease 
calpain which regulates many cellular processes with its proteolytic activity. Known 
substrates of calpain are cytoskeletal and membrane proteins. Therefore calpain 
regulates amongst others granule secretion and cell spreading [96]. Furthermore, 
platelets express many other proteases but essential here is that platelets possess 
the special protease, the proteasome, which is one of the main systems to degrade 
proteins [59, 97]. The proteasome is discussed in the following section. 
All in all, anucleate platelets seem to have complex degradation systems [98].  
 
1.3 The proteasome, a multicatalytic enzyme 
Proteolysis is very important to regulate cellular protein levels and there exist two 
main pathways to degrade proteins in eurkaryotes. The lysosomal and the ubiquitin 
proteasome system are responsible for intracellular protein turnover [99, 100]. Since 
its discovery the ubiquitin proteasome system came into focus expanding the role of 
proteolysis from mere housekeeping to regulator of major cellular processes. It plays 
a crucial role in regulating the cell cycle, division, survival, oncogenesis, transcription, 
development, selective elimination of abnormal proteins, and antigen processing 
[101-104]. The protein to be degraded, the substrate, is tagged by a polyubiquitin 
chain to one of its lysine residues. This tagging is performed by a series of enzyme-
mediated reactions. First, ubiquitin is activated by ubiquitin-activating enzyme (E1), 
the activated ubiquitin is brought to an ubiquitin-conjugating enzyme (E2) and finally 
ubiquitin is ligated to the lysine residue of the substrate through the action of an E3 
ligase. Further activated ubiquitins are attached to internal lysine residues within the 
already attached ubiquitin to form polyubiquitin chains. The polyubiquitin tag is 
recognized by the 26S proteasome. The proteasome, just one single protease, has 
the central role of degrading the protein in the ubiquitin proteasome system [105, 
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106]. Indeed regulation of the proteasome occurs on muliple levels, is extraordinarily 
complex and not fully understood until today. The left panel of Figure 6 illustrates the 
ubiquitin proteasome system. Degradation products are short peptides that can be 
recycled to produce new proteins and the polyubiquitin tag can be hydrolyzed and 
reused as well.  
 
1.3.1 Structure and complexity of the proteasome 
The proteolytic component of the ubiquitin proteasome system is the 26S 
proteasome, which consists of two 19S (PA700) regulatory particles and a core 
particle, the 20S proteasome.  
 
The 20S core particle 
The 20S proteasome is a 700kDa, cylinder-shaped protease with four stacked 
heptameric rings. This cylinder contains 28 protein subunits that are arranged in a 
specific way, two outer α rings and the two inner β rings (α7β7β7α7) [107, 108]. The 
outer rings interact with the 19S particles and the inner rings harbor the proteolytic 
activites. In eurkaryotes three β-type subunits contain proteolytically active centers 
[107]. Their activity comes from their N-terminal threonine residue, which acts as a 
nucleophile. Therefore proteasomes are classified as N-terminal nucleophilic 
hydrolases/proteases [109]. The β5, β2, and β1 subunits contain the active centers 
and according to their distinct cleavage preferences they are termed chymotrypsin-
like, trypsin-like, and caspase-like activities, respectively (CT-L, T-L, C-L) [110, 111]. 
The interior of the cylinder contains a cavity consisting of three contiguous chambers 
joint by narrow constrictions [107, 108]. The right panel of Figure 6 clarifies the 
structure of the 20S core particle of the proteasome. The structure indicates that 
substrates enter through a gated-channel [112]. The unfolded amino acid chains are 
brought through the particle in a continuous way and each active site can cleave the 
chain after specific amino acid residues. The CT-L activity (β5 subunit) cuts after 
hydrophobic amino acid residues [110], the T-L activity (β2 subunit) after basic amino 
acid residues [110] and the C-L activity (β1 subunit) cleaves peptide bonds after 
acidic and branched-chain amino acids [110, 111, 113, 114].  
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Figure 6: The ubiquitin proteasome system simplified with its central protein, the proteasome. 
The right panel pictures a schematic view of the ubiquitin proteasome system. Ub: ubiquitin, E1: 
ubiquitin-activating enzyme, E2: ubiquitin-conjugating enzyme, E3: a ligase. Left panel: The structure 
of a 20S core particle with its four heptameric rings stacked together [112].  
 
Proteasome regulators and the formation of different complexes 
There are various types of intracellular proteasomes because the catalytic core 
protein can be associated to several types of regulatory subunits (the 19S and the 
11S particle) and it can be associated to just one or two regulatory subunits [115-
117]. In vitro, the 20S core alone cannot degrade large proteins. They have to be 
denatured and the 20S core needs to be activated which happens with SDS, heat or 
specific ionic conditions [118, 119]. The exact mechanism for this is unclear. Under 
physiological conditions a regulatory particle can perform this activation of the 20S 
core. 
The 19S regulatory particle is 700kDa and organized in a base and a lid where the 
base is attached to one of the terminal rings of the 20S core particle [120, 121]. The 
19S aids in substrate recognition, untagging and unfolding [122-124]. Additionally, 
the 19S mediates conformational changes in the 20S core to let a substrate enter the 
core cavity. The 19S regulator consists of six ATPases and 15 additional subunits. 
Unfolding, allowing entrance to the 20S core and cutting off the polyubiquitin tag are 
ATP-dependent functions of the 19S [125]. Even though the 19S regulatory particle 
recognizes polyubiquitinated proteins that are to be degraded there is evidence that 
an ATP-dependent but ubiquitin-independent degradation by the 19S/20S particle of 
just a few proteins exists [126, 127].  
The 11S (PA28) is another regulator that functions in an ATP- and ubiquitin-
independent manner [128, 129]. It also associates with both or one of the terminal 
rings of the 20S core particle. The 11S is approximately 200kDa and opens the 
entrance for short peptides to the cavity of the 20S core [128, 129]. Those short 
peptides processed by the 11S-20S have been associated with antigen presentation 
on MHC I molecules [130, 131]. For its relevance in processing antigens for MHC I 
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presentation this 11S particle coupled to the 20S core is referred to as the 
immunoproteasome. The immunoproteasome is not only the 20S core particle with 
the 11S regulator but three of the subunits of the core are replaced by other subunits. 
In this way the cleavage specificity of peptides by the proteasome is altered in a 
manner that favors production of antigenic peptides [130]. 
Furthermore, hybrid complexes like 11S+20S+19S were discovered [115, 117] in 
eukaryotic cells but their functional role remains to be determined.  
Figure 7 shows electron microscopy pictures of different proteasome complexes in an 
eukaryotic cell.  
 
Figure 7: Electron micrographs of different proteasome complexes. 20S and 26S proteasomes 
were purified from rabbits and murine 11S proteasomes were recombinant expressed in E. coli. 
Modified from Cascio et al. [115].  
 
1.3.2 Proteasome inhibitor classes 
To understand an enzyme, the investigative tool of inhibiting its activity has been 
widely used. For many years the classes and mechanisms of proteasome inhibitors 
had been studied but only in 1995 with the ability to crystallize the huge protein 
complex, the proteasome, the exact biochemical mechanism of the proteasome could 
be suggested [108]. The proteasome can be classified as a threonine protease, a 
new family of proteases. Even though the three catalytic activities of the proteasome 
have distinct substrate specificities they share a common mechanism. An N-terminal 
threonine hydroxyl group at each active site serves as a nucleophil. With the help of 
one water molecule a peptide bond is cleaved [108, 132, 133]. 
There exist various natural and synthetic compounds that inhibit the proteasome. 
Most of them can be classified into groups but several new classes were and are 
identified through the synthesis of chemically modified versions of already existing 
inhibitors. 
Synthetic reversible peptide aldehydes, such as leupeptin or MG132 are widely used 
to inhibit the proteasome in vitro and in vivo. Most of them inhibit primarily the CT-L 
activity but are capable of modifying all three activities at high concentrations [107]. 
Unfortunately, they interact with serine and cysteine proteases as well and therefore 
they are not selective for the inhibition of the proteasome [134]. Peptide boron acids 
do not cross-react with cysteine proteases but are still not highly specific for the 
proteasome. The dipeptide boronic acid bortezomib has been approved for treatment 
of multiple myeloma patients [135]. Bortezomib preferentially inhibits the CT-L 
acitivity, to a lesser extent the C-L activity but the T-L activity is left untouched [136, 
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137]. Only the crystallization of the 20S core with bortezomib gave an explanation for 
its different binding affinities to the three active sites [137]. The individual side chains 
of the inhibitor interact different with protein specificity pockets. 
The natural compound lactacystin is a specific proteasome inhibitor that forms an 
intra-molecular lactone, which reacts then with the active site threonine [138]. 
Unfortunately lactacystin inhibits cathepsin A too [139]. In addtion, the synthesis is 
not as cheap and therefore its frequent use is limited.  
Epoxomicin is another natural occurring highly specific proteasome inhibitor [140]. 
Epoxomicin belongs to the group of α’,β’ epoxyketones, where a highly stable six-
member ring is formed. There is no cross-reactivity of epoxomicin known.  
 
1.3.3 Regulation of the proteasome 
Due to the diverse functions of the proteasome the regulation of the proteasome 
seems complex and is not fully understood. The proteasome does not only degrade 
proteins it plays an essential role in regulating the cell cycle, division and survival, 
oncogenesis, transcription, development, selective elimination of abnormal proteins, 
and antigen processing [101-104]. The regulation of the proteasome seems to result 
from proteins associating with the proteasome, from the different proteasome 
complexes itself, from an induction of specific proteasome subunits or 
posttranscriptional modifications of proteasome subunits.  
It is known that the 11S regulator associated with the 20S core proteasome 
preferentially processes peptides for antigen presentation [130, 131]. The induction 
of specific proteasome subunits, as in the immunoproteasome, regulates also the 
function of the proteasome with a preference for processing antigens [141].  
Associating partners of the proteasome are, for instance, PKA, and casein kinase II 
(CKII) [142, 143]. 
Subunits Rpt6 (PSMC5) and Rpt2 (PSMC1) of the 19S regulatory particle are known 
to undergo posttranscriptional modifications and influencing the proteasome activity 
in this way. The ATPase subunit Rpt6 is phosphorylated by PKA and based on this 
the proteasome is activated [144]. On the contrary, when the ATPase subunit Rpt2 is 
O-linked with N-acetylglucosamine, proteasome activity is suppressed [145]. Indeed, 
other subunits are posttranscriptional modified as well [146].  
Additionally, recent studies demonstrated that the proteasome is able to cleave 
proteins and not degrade them. This proteasomal protein processing is a novel 
function of the proteasome. Some proteins are not completely degraded by the 
proteasome but degradation yields biologically active protein fragments. The 
transcription factors NFκB, and distant homologues of NFκB (Spt23p, Mga2p) are 
generated from precursors by the proteasome [147-149]. Recently, Gupta et al. 
indicated proteasomal cleavage of cytoskeletal proteins Filamin A and Talin-1 [150]. 
Some models of this novel mechanism of the proteasome have been discussed but 
the underlying process remains to be studied in detail [151].  
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1.3.4 Involvement of the proteasome in disease 
Since most intracellular proteins are degraded by the proteasome and the 
proteasome plays an essential role in many cellular processes, an influence or 
abnormalities of the proteasome have been mentioned in many diseases. Proteolysis 
with the proteasome as one of its major initiators is crucial in nucleated as well as 
anucleate cells.  
Formation of amyloid fibers in Alzheimer’s disease could arise from proteasome 
defects [152]. In early stages of atherosclerosis the proteasome has been found to 
be involved [153]. As an example, in smoth muscle cells the proteasome favors a 
conversion from a contractile to a metabolic phenotype promoting atherosclerosis 
[154]. Moreover, Tisdale et al. demonstrates that muscle proteolysis comes from the 
increased activity and expression of the proteasome. Therefore to prevent muscle 
proteolysis, which is common in diseases such as sepsis, he suggests the ubiquitin 
proteasome pathway as a therapeutic target [155].  
Already long ago proteasome inhibitors were identified to have antitumor effects and 
nowadays proteasome inhibitors as bortezomib or carflizomib are used as 
therapeutic agents [135, 156]. Bortezomib (Valcade®) was already approved in 2003 
in multiple myeloma. In malignant cells a persistent proteasome inhibition results in 
growth arrest and apoptosis reducing tumor tissue [157]. Therefore improvement and 
synthesis of novel or second generation proteasome inhibitors are of huge relevance 
for cancer therapeutics [158]. 
 
1.3.5 The proteasome in anucleate platelets 
Considering the highly conserved structures and functions of the proteasome in 
eukaryotic cells, the discovery of the proteasome in platelets seemed a logical 
finding. Already in 1991 Yukawa et al. purified the platelet proteasome [59] and in 
1993 a proteasome activator in platelets was described [159]. Ostrowska et al. 
confirmed the identity of a proteasome in platelets and showed evidence of the 11S 
regulator in human platelets [160].  
Even though the CT-L activity of the 20S proteasome from platelets was already 
measured by Yukawa et al. and Ostrowska et al., detailed analysis of the regulation 
and function of the proteasome in platelets had not been provided for a long time.  
Only when proteasome subunits were found to be downregulated in patients [161, 
162], further studies followed. The importance of protein degradation and therefore 
the proteasome in anucleate platelets was implied in 2013 [98].  
The 20S CT-L proteasome activity can be regulated. It was found to increase in 
response to agonist stimulation [163] but other activities had not been studied.  
The 11S regulator was already mentioned in the past and there is data  on individual 
proteasome subunits in platelets [60] but Klockenbusch et al. only recently published 
detailed proteomic analysis identifying nearly all subunits of the 26S proteasome in 
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human platelets [63]. They also discovered that platelets have an active 
immunoproteasome [63] which is of relevance since platelets present antigens as 
well (see section 1.2.3).  
In megakaryocytes the proteasome is essential for platelet production [164]. But the 
importance of the proteasome in platelets has not been tested in detail. It is just 
mentioned that the proteasome might play a role in activation and aggregation [150]. 
Gupta et al. stated that low concentrations of thrombin reduced aggregation and 
thrombin and ADP stimulation suppressed microparticle shedding. They 
demonstrated that Filamin A and Talin-1, cytoskeletal proteins, are ubiquitinated and 
then cleaved by the proteasome in platelets. They hypothesize that the platelet 
proteasome modifies cytoskeletal proteins and promotes platelet activation. More in 
depth analysis is necessary to support this data and to find out the exact role of the 
proteasome in platelet activation.  
 
1.4 Aim of the study 
Platelets play an important role in vascular integrity and more extended functions of 
platelets have been described. Protein synthesis and degradation are essential 
processes in cells and although the last decade has shown that platelets also 
synthesize proteins de novo, the role of degradation in anucleate platelets is not fully 
understood. Thus, a more detailed knowledge of the proteolytic systems in platelets 
is necessary. In this context the proteasome as one of the major proteolytic systems 
has merely been studied in platelets.  
 
Therefore we aimed to characterize the role of the proteasome in human platelets 
from a functional perspective. For this purpose a central function of platelets, 
aggregation was tested in regard to the role of the proteasome. Aggregation was 
analyzed under proteasome inhibitor treatment. Next, an activation of the proteasome 
including all proteolytic subunits by known platelet agonists, such as thrombin, ADP, 
and collagen was to be examined.  
In order to explain the role of the proteasome in platelets, associated signaling 
pathways must be shown. Consequently, a connection of one signaling pathway with 
the proteasome under platelet agonist treatment was surveyed. The NFκB pathway 
has been identified in platelets and affects platelet aggregation. Since the inhibitory 
protein of NFκB, IκBα, is a proteasome substrate a connection of the proteasome 
and NFκB pathway in platelet aggregation was inspected. Moreover, shape change 
plays a crucial role during platelet aggregation and platelets contain a large amount 
of actin. Thus, it was important to investigate cytoskeletal protein processing as well. 
For that reason, cytoskeletal protein cleavage was viewed with proteasome inhibition.  
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In summary, this thesis has the intention to enlighten the role and function of the 
proteasome in human platelets with regard to aggregation, cytoskeletal protein 
regulation, connection to the NFκB pathway as well as potential underlying 
mechanisms (Figure 8).  
 
 
 
Figure 8: Aim of the study. What is the function of the proteasome in human platelets? Is there an 
impact of the proteasome on cytoskeletal proteins? Is there a connection of the NFκB pathway and the 
proteasome in platelets? Plt: platelet 
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2 Material and Methods 
 
2.1 Material 
2.1.1 Instruments 
12-channel pipette 200μl Eppendorf, Hamburg, Germany 
Aggregometer 490-2D Chrono-log Corporation, Havertown, 
USA 
BD FACS Canto II Becton Dickinson, Franklin Lakes, 
USA 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Coulter® Ac∙T diff™ Beckman Coulter, Krefeld, Germany 
Digital CCD Camera Controller ORCA-
ER 
Hamamatsu Photonics, Hamamatsu, 
Japan 
Fixed-angle rotor F-45-30-11 Eppendorf, Hamburg, Germany 
Handystep electronic Brand, Wertheim, Germany 
Heraeus Megafuge 1.0 Heraeus, Hanau, Germany 
Horizontal table top autoclave Systec DE-
65 
Systec, Linden, Germany 
Ice machine Scotsman AF 100 Scotsman, Vernon Hills, USA 
Incubator Heraeus B 5042 Heraeus, Hanau, Germany 
Incubator Heraeus Function Line Heraeus, Hanau, Germany 
Inverted microscope CKX41 Olympus, Shinjuku, Japan 
Microcentrifuge 5815R Eppendorf, Hamburg, Germany 
Microflow biological safety cabinet Nunc, Wiesbaden, Germany 
Microplate reader FLUOstar BMG Labtech, Worcester, USA 
Microplate reader Tecan Spectra Fluor Tecan Group, Männedorf, 
Switzerland 
Multichannel pipette Transferpette S Brand, Wertheim, Germany 
Multipipette puls Eppendorf, Hamburg, Germany 
Multiplate Analyzer Roche, Basel, Switzerland 
Ocular lens 10x and 40x Olympus, Shinjuku, Japan 
PerfectBlue Dual Gel System Twin S Peqlab, VWR, Erlangen, Germany 
PerfectBlue Tank Electro Blotter Web S Peqlab, VWR, Erlangen, Germany 
Pipette aid accu-jet pro Brand, Wertheim, Germany 
Pipettes Research® 2,5μl, 10µl, 100μl, 
200µl, 1000µl, 5000μl 
Eppendorf, Hamburg, Germany 
Pipettes Research® Plus 20µl, 200µl, 
1000µl 
Eppendorf, Hamburg, Germany 
PowerPac Basic Bio-Rad Laboratories, Hercules, 
USA 
Shaker Polymax 1040 Heidolph Instruments, Schwabach, 
Germany 
Spectral photometer UV-1602 Shimadzu, Kyoto, Japan 
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Standard Power Pack P25 Biometra, Göttingen, Germany 
Swing-bucket rotor A-4-62 Eppendorf, Hamburg, Germany 
Tankblot Eco Mini Biometra AnalytikJena, Jena, Germany 
  
ThermoCell cooling heating block HB 202 Biozym Scientific, Hessisch 
Oldendorf, Germany 
Vortexer Kisker Biotech, Steinfurt, Germany 
Waterbath WBN 10 Memmert, Schwabach, Germany 
Weighing scale Acculab ALC 110.4 Sartorius, Göttingen, Germany 
 
2.1.2 Glas and platic labware 
Brand® cuvette semi-micro Brand, Wertheim, Germany 
Brandplates® microplates 96-wells black Brand, Wertheim, Germany 
Cell culture dish 100 x 20mm Sarstedt, Nümbrecht, Germany 
Cell culture flask 75cm2 Greiner Bio-One, Kremsmünster, 
Austria 
Cell scraper 2-position blade 25 Sarstedt, Nümbrecht, Germany 
Corning® centrifuge tubes (15, 50ml) Corning Incorporated, New York, 
USA 
CryoPure cryo tube 1.6ml Sarstedt, Nümbrecht, Germany 
Fast-Read 102® Biosigma, Cona, Italy 
Gazin® gauze ball plum-size Lohmann & Rauscher, Rengsdorf, 
Germany 
Glass cuvettes 450µl Probe & Go, Osburg, Germany 
Injekt™ syringe 20ml Braun, Melsungen, Germany 
Micro tube 0.5ml, 1.5ml, 2ml Sarstedt, Nümbrecht, Germany 
Micro tube 1.5ml brown Sarstedt, Nümbrecht, Germany 
Micro tube 1.5ml low binding Sarstedt, Nümbrecht, Germany 
Microtest plate 96-well, flat base Sarstedt, Nümbrecht, Germany 
Multiply®-Pro cup 0.2ml Sarstedt, Nümbrecht, Germany 
Nalgene™ Rapid-Flow™Filter Unit, pore 
0.2µm 
Thermo Scientific, Waltham, USA 
Parafilm M® Pechiney Plastic Packaging, 
Chicago, USA 
Pasteur pipettes GPP 1.0 Kisker Biotech, Steinfurt, Germany 
Petri dish 92x16mm with cams Sarstedt, Nümbrecht, Germany 
Pipette tips (20µl, 200µl, 1ml, 5ml) Sarstedt, Nümbrecht, Germany 
Protective gloves Vasco® Basic Braun, Melsungen, Germany 
Safety-Multifly® needle 21G Sarstedt, Nümbrecht, Germany 
Serological pipettes nonsteril (10ml, 
25ml) 
Sarstedt, Nümbrecht, Germany 
Serological pipettes steril (1ml, 2ml, 5ml, 
10ml, 25ml) 
Sarstedt, Nümbrecht, Germany 
Single use filter unit, 0.2µm Sartorius, Göttingen, Germany 
S-Monovette® Sarstedt, Nümbrecht, Germany 
Stir bars siliconized Probe & Go, Osburg, Germany 
Tube 11.5ml Sarstedt, Nümbrecht, Germany 
Tube 5ml Sarstedt, Nümbrecht, Germany 
Various laboratory glassware Brand, Wertheim, Germany 
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Various laboratory glassware Duran Group, Mainz, Germany 
2.1.3 Inhibitors, chemicals and reagents 
Inhibitors 
Bay 11-7082 NFκB inhibitor Sigma-Aldrich, Seelze, Germany 
Bortezomib Proteasome inhibitor Merck Millipore, Billerica, USA 
Epoxomicin Proteasome inhibitor Merck Millipore, Billerica, USA 
Lactacystin Proteasome inhibitor Enzo Biochem, Farmingdale, USA 
MG132 (Z-Leu-
Leu-Leu-al) 
Proteasome inhibitor Sigma-Aldrich, Seelze, Germany 
Ro 106-9920 NFκB inhibitor Tocris, Bristol, England 
Z-Pro-Nle-Asp-
CHO 
Proteasome inhibitor Enzo Biochem, Farmingdale, USA 
 
Chemicals for platelet activation 
Adenosine diphosphate Sigma-Aldrich, Seelze, Germany 
Adenosine diphosphate (ADPtest) Roche, Basel, Switzerland 
Collagen (COLtest) Roche, Basel, Switzerland 
Thrombin from bovine plasma  Sigma-Aldrich, Seelze, Germany 
TRAP-6 (H-Ser-Phe-Leu-Leu-Arg-Asn-OH) Bachem, Bubendorf, Switzerland 
 
Chemicals and reagents 
A23187 Merck Millipore, Billerica, USA 
Acetic acid 100% Merck, Darmstadt, Germany 
Acrylamide Panreac AppliChem, Cheshire, USA 
Adenosine triphosphate Sigma-Aldrich, Seelze, Germany 
Agarose Panreac AppliChem, Cheshire, USA 
Aminomethylcoumarin Biomol, Hamburg, Germany 
Ammonium persulfate (APS) Panreac AppliChem, Cheshire, USA 
Bacto-Yeast Extract Panreac AppliChem, Cheshire, USA 
Bovine serum albumin (BSA), Fraction V Panreac AppliChem, Cheshire, USA 
Bromophenol blue Sigma-Aldrich, Seelze, Germany 
Calcium choride Merck, Darmstadt, Deutschland 
Cell Lysis Buffer 10x Cell Signaling, Danvers, USA 
Color Prestained Protein Standard, 
Broad Range 
New England Biolabs, Ipswich, USA 
cOmplete Mini Protease Inhibitor 
Cocktail Tablets 
Roche, Basel, Switzerland 
D-Glucose Merck, Darmstadt, Deutschland 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Seelze, Germany 
Disodium hydrogen phosphate Sigma-Aldrich (former Fluka), Seelze, 
Germany 
Dithiothreitol (DTT) Panreac AppliChem, Cheshire, USA 
DMEM Sigma-Aldrich, Seelze, Germany 
Endopan 3, Basal Medium for 
Endothelial Cells 
PAN-Biotech, Aidenbach, Germany 
Ethanol 70% Panreac AppliChem, Cheshire, USA 
Ethanol 99% Panreac AppliChem, Cheshire, USA 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt, Deutschland 
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Fetal Bovine Serum Biochrom by Merck, Darmstadt, 
Deutschland 
Glycerol Panreac AppliChem, Cheshire, USA 
Glycine Panreac AppliChem, Cheshire, USA 
HEPES Panreac AppliChem, Cheshire, USA 
Hydrogen peroxide Panreac AppliChem, Cheshire, USA 
IGEPAL® CA-630 Sigma-Aldrich, Seelze, Germany 
Iloprost (Ilomedin®) Bayer Schering Pharma AG, Berlin, 
Germany 
Ionomycin Cayman Chemical, Ann Arbor, USA 
Isopropanol Panreac AppliChem, Cheshire, USA 
Luminol Panreac AppliChem, Cheshire, USA 
Magnesium chloride Merck, Darmstadt, Deutschland 
Medium 199 Sigma-Aldrich, Seelze, Germany 
Methanol Panreac AppliChem, Cheshire, USA 
Monosodium phosphate Merck, Darmstadt, Deutschland 
Nonfat dried milk powder Panreac AppliChem, Cheshire, USA 
PageRuler Plus Prestained Protein 
Ladder 
ThermoScientific, Waltham, USA 
p-Coumaric acid Sigma-Aldrich (former Fluka), Seelze, 
Germany 
Penicillin-Streptomycin Sigma-Aldrich, Seelze, Germany 
Phenylmethylsulfonyl fluoride Sigma-Aldrich, Seelze, Germany 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich, Seelze, Germany 
Ponceau S solution Sigma-Aldrich (former Fluka), Seelze, 
Germany 
Potassium chloride Panreac AppliChem, Cheshire, USA 
Potassium dihydrogen phosphate Merck, Darmstadt, Deutschland 
Precise Tris-Glycine Gels 8-16% ThermoScientific, Waltham, USA 
purified human proteasome 20S Enzo Biochem, Farmingdale, USA 
RPMI 1640 Biochrom, Berlin, Germany 
ServaGel™TG Prime™ 8-16% Serva Electrophoresis, Heidelberg, 
Germany 
Sodium bicarbonate Sigma-Aldrich, Seelze, Germany 
Sodium chloride Panreac AppliChem, Cheshire, USA 
Sodium dodecyl sulfate (SDS) Panreac AppliChem, Cheshire, USA 
Sodium hydroxide Roth, Karlsruhe, Germany 
ß-Mercaptoethanol Sigma-Aldrich, Seelze, Germany 
TEMED Panreac AppliChem, Cheshire, USA 
Tris (Tris(hydroxymethyl)-aminomethan) Panreac AppliChem, Cheshire, USA 
Trisodium citrate solution 0,11M Waldeck, Münster, Germany 
Triton-X 100 Sigma-Aldrich, Seelze, Germany 
Trypan blue Sigma-Aldrich, Seelze, Germany 
Trypsin 10x Sigma-Aldrich, Seelze, Germany 
Tryptone CULTIMED Panreac AppliChem, Cheshire, USA 
Tween® 20 Panreac AppliChem, Cheshire, USA 
Whatman filter paper GE Healthcare, Munich, Germany 
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2.1.4 Bacteria strains 
The uropathogenic Escherichia coli (UPEC) strain UTI89 was analyzed during this 
study, along with its generated knockouts for hlyA and cnf1. HlyA, α-hemolysin, is a 
pore-forming toxin and cnf1 is the cytotoxic necrotizing factor 1. The targeted 
knockouts were created using the lambda Red-mediated linear transformation 
system. Those strains were provided by M.A. Mulvey, University of Utah [165]. Form 
“Z” is on hand and approved.  
 
UTI89 
UTI89 ΔhlA::kan 
UTI89 Δcnf-1::clm 
UTI89 ΔhlA::kan Δcnf-1::clm 
 
2.1.5 Kits 
20S Proteasome Activity Assay Merck Millipore, Billerica, Germany 
BCA Protein Assay Kit ThermoScientific, Waltham, USA 
MitoPT™ JC-1 Assay Kit ImmunoChemistry, Bloomington, USA 
NFκB (p65) Transcription Factor Assay 
Kit 
Abnova, Taipei, Taiwan 
 
2.1.6 Gel preparations for SDS-PAGE home-made gels 
 
 
 
 
 
 
 
 
 
 
 
 
Separating gels    Stacking gel  
 10% 12%   4% 
Acrylamide (30%) 15ml 18ml  Acrylamide (30%) 2.6ml 
1.5M Tris pH 8.8 11.335ml 11.335ml  0.5M Tris pH 6.8 5ml 
10% SDS 450µl 450µl  10% SDS 0.2ml 
Destilled H2O 18.2ml 15.2ml  Destilled H2O 12ml 
APS (10%) 250µl 250µl  APS (10%) 200µl 
TEMED 25µl 25µl  TEMED 40µl 
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2.1.7 Primary antibodies used for western blotting 
Antibody Host Blocking, 
Dilution 
and buffer 
Gel used Amount of 
protein 
loaded 
Company 
Anti-Bcl-x Mouse (MC) 5% milk, 
1:330 in A 
from 
ThermoScientific 
20µg Becton 
Dickinson, 
Franklin 
Lakes, USA 
Anti-Filamin A Rabbit (PC) 5% BSA, 
1:1000 in 
TBS-T 
Home-made 
10% gel 
20µg Cell 
Signaling, 
Danvers, 
USA 
Anti-Talin-1 Rabbit (MC) 5% milk, 
1:1000 in B 
from Serva 20µg Cell 
Signaling, 
Danvers, 
USA 
Anti-Ubiquitin 
(A-5) 
Mouse (MC) 5% BSA, 
1:500 in  
TBS-T 
any 20µg Santa Cruz, 
Dallas, USA 
Anti-PSMA3 Rabbit (MC) 5% BSA, 
1:1000 in 
TBS-T 
Home-made 
10% gel 
20µg Cell 
Signaling, 
Danvers, 
USA 
Anti-
PSMC5/TRIP1 
Rabbit (PC) 5% BSA, 
1:1000 in 
TBS-T 
Home-made 
10% gel 
20µg Cell 
Signaling, 
Danvers, 
USA 
Anti-PA28α Rabbit (MC) 5% BSA, 
1:1000 in 
TBS-T 
Home-made 
10% gel 
20µg Cell 
Signaling, 
Danvers, 
USA 
Anti-Human 
IκBα 
Mouse (MC) 5% milk, 
1:500 in B 
From Serva 60µg Becton 
Dickinson, 
Franklin 
Lakes, USA 
Anti-β-Catenin Rabbit (PC) 5% BSA, 
1:1000 in 
TBS-T 
Home-made 
10% gel 
60µg Cell 
Signaling, 
Danvers, 
USA 
Anti-phospho-
IKKα(Ser176)/ 
IKKβ(Ser177) 
Rabbit (MC) 5% milk, 
1:1000 in B 
Home-made 
10% gel 
60µg Cell 
Signaling, 
Danvers, 
USA 
Anti-β-Actin 
(13E5) 
Rabbit (MC) 1:2000 in 
TBS-T 
any 20µg-60µg Cell 
Signaling, 
Danvers, 
USA 
Table 1: Primary antibodies used for western blotting. MC: monoclonal; PC: polyclonal 
 
Blocking occurred either in 5% milk or 5% BSA in TBS-T. TBS-T contains 50mM Tris, 
150mM NaCl and 0.1% Tween. For buffer A 3% milk in TBS-T were prepared and 
buffer B consists of 5% BSA in TBS-T. 
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2.1.8 Secondary antibodies peroxidase conjugated used for western 
blotting 
Antibody Host Dilution Company 
Anti-rabbit IgG Goat 1:2000 in TBS-T Merck Millipore, 
Billerica, USA 
Anti-mouse 
IgG 
Goat 1:2000 in TBS-T Merck Millipore, 
Billerica, USA 
Table 2: Secondary antibodies used for western blotting. 
 
2.1.9 Substrates for proteasome acitivity analysis 
Chymotrypsin-like 
activity 
Suc-Leu-Leu-Val-Tyr-AMC Bachem, Bubendorf, 
Switzerland 
Trypsin-like activity Boc-Leu-Ser-Thr-Arg-AMC Bachem, Bubendorf, 
Switzerlad 
Caspase-like activity Z-Leu-Leu-Glu-AMC Boston Biochem, 
Cambridge, USA 
 
2.2 Methods 
2.2.1 Cultivation and handling of used cell lines 
Cell culture work was carried out under sterile conditions within a cell culture hood. 
The adherent human microvascular endothelial cells (HMEC) were provided by Ades 
et al. [166]. HMECs were cultivated in Dulbecco’s Modified Eagle Medium (DMEM) 
enriched with 10% fetal calf serum (FCS), 10% endothelial growth medium and 1% 
penicillin/streptomycin at 37°C with 5% CO2 and at 95% humidity. When cells 
reached confluency they were splitted, mostly twice a week 1:3, to avoid contact 
inhibition. For subculturing the adherent cells were gently washed with PBS (137mM 
NaCl, 2.7mM KCl, 8mM Na2HPO4 and 1.5mM KH2PO4, pH 7.4) and then treated with 
the serine protease trypsin until cells began to float. To stop the trypsin reaction and 
prevent cell damage the 2-fold amount of complete culture medium (compared to the 
trypsin solution) was added. One third of this cell suspension was given to a new cell 
culture dish with the adequate amount of cultivation medium.  
The human leukaemia cells HL-60 (ACC-3) were obtained from German Resource 
Centre for Biological Material (Braunschweig, Germany). Those suspension cells are 
an acute myeloid leukemia cell line. They were established from the peripherial blood 
of a 35-year-old woman with acute myeloid leukemia (AML FAB M2) in 1976. They 
can be used for induction of differentiation studies. Here they were used as a 
nucleated control cell line. HL-60 cells were cultivated in RPMI 1640 medium 
enriched with 10% fetal calf serum (FCS) and 1% penicillin/streptomycin at 37°C with 
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5% CO2 and at 95% humidity. These suspension cells were cultivated in culture 
flasks 75cm2 and splitted, mostly twice a week, to maintain them at 0.5-1 x 106 
cells/ml. To split these suspension cells 1 x 106 cells were pelleted, washed with PBS 
and given to a new culture dish with the adequate amount of cultivation medium. 
Cells were counted using a Fast-Read 102® chamber and calculated accordingly. 
For the exclusion of dead cells trypan blue was added 1:5 to the cell suspension. 
Only viable (unstained) cells in 4 squares were counted.  
 cells ml� =  cell count4 (squares)  × 5 (dilution factor) × 104(chamber volume) 
 
2.2.2 Thawing and freezing of cell lines 
Cells were stored in a liquid nitrogen tank and when needed thawed rapidly at 37ºC. 
One vial HMEC cells was added to a culture dish with fresh cultivation medium. After 
4-5 hours when all HMEC cells adhered new media was added. When confluent the 
cells were split normally. One vial of the suspension cells HL-60 was given to fresh 
cultivation medium and pelleted immediately to dispose the antifreezing agent 
DMSO. The pellet was given to a culture flask with fresh cultivation medium and 
cultivated as described under 2.2.1. 
To freeze cells the pellet was resuspended in 90% FCS containing 10% antifreezing 
agent DMSO after a normal splitting step. HL-60 cells from a one culture flask were 
divided to three cryogenic vials. The pellet from one 10cm dish with confluent HMEC 
cells was frozen in one cryogenic vial. With an isopropanol filled freezing aid the vials 
were brought to -80°C (1°C/min). After 24h the cells were stored in a liquid nitrogen 
tank. 
 
2.2.3 Platelet isolation 
Blood samples were taken from healthy volunteers. Whole blood was drawn directly 
into plastic tubes containing sodium citrate (1:10). Sodium citrate is an effective 
anticoagulant which binds the calcium ions so that coagulation proteins cannot 
perform their tasks. After centrifugation of the whole blood without brake at 340g for 
15 minutes at room temperature (RT), the platelet-rich plasma (PRP) was carefully 
removed and given to preheated platelet buffer (1:5) in the presence of 2ng/ml 
iloprost and pelleted at 600g for 10 minutes at RT. Platelet buffer contains 138mM 
NaCl, 2.7mM KCl, 12mM NaHCO3, 0.4mM NaH2PO4, 1mM MgCl2 x 6H2O, 5mM D-
Glucose and 5mM HEPES, was adjusted to pH 7.35 and sterile filtered. Iloprost is an 
analogue of prostacyclin, a reversible platelet inhibitor [167]. Then the pellet was 
gently resuspended in platelet buffer. The platelet number was measured by a 
Beckman Coulter Ac-T Diff™ Analyser in a 1:10 diluted aliquot and platelet purity was 
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determined to be >99.5%. Contamination often was found to be at the lower limit of 
detection of the instrument. The Beckman Coulter Ac-T Diff™ Analyser is used in 
clinical laboratories to quantify automatically hematological values. In whole blood 
parameters, such as the leukocyte count, number of erythrocytes, hemoglobin 
concentration, hematocrit and number of platelets is analyzed using the Coulter 
technique. The Coulter principle is based on the change of impedance that occurs 
when particles pass a small capillary in an electrolyte. One pulse of impedance refers 
to the number of particles and the pulse height refers to the size of the particle [168]. 
The use of the Coulter Analyser to count platelets is described before [169]. 
2.2.4 Platelet stimulation 
Washed platelets (up to 2x108 cells/ml) were incubated in warm platelet buffer in 5ml 
plastic tubes at 37°C for indicated times with indicated stimuli. To pellet the cells they 
were transferred to 1.5ml micro tubes (protein low binding surface) and centrifuged at 
600g for 2.5 minutes at RT. The pellet was lysed with the appropriate lysis buffer 
depending on the experiment.  
 
2.2.5 Patient studies 
Handling of blood from patients 
Patients were recruited from the medical intensive care unit, intermediate care unit 
and emergency room of the University Medical Center Innenstadt of the University 
Hospital Munich. All patients were above 18 years and written informed consent was 
obtained from patients (control patients included) or next of kin. Blood was drawn 
within the first 48 hours of admission in all patients diagnosed with sepsis and 
controls. In the group of patients with severe sepsis, follow-up blood draws were 
taken according to the clinical follow-up assessment of the patient by the critical care 
team (see also Study population). Platelets were isolated as described under 2.2.3 
but under security level S2. 
Purification and resuspension of platelets in equal volumes and at equal 
concentrations guaranteed identical processing conditions and equalized the initial 
differences in platelet number among the clinical samples. 
 
Study population  
26 Patients with the diagnosis of sepsis or sever sepsis, including septic shock as 
previously defined were included in the study between January 2012 and January 
2013 [170, 171]. Clinical disease severity was assessed with Acute Physiology and 
Chronic Health Evaluation II (APACHE II), Sequential Organ Failure Assessment 
(SOFA), and Simplified Acute Physiology Score II (SAPS II) on the days of blood 
draws. Severe sepsis was defined as sepsis complicated by organ failure [171]. We 
considered organ failure as a SOFA point score above 2, as previously used by 
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others [172-174]. Subsequently, the patient collective comprised nine patients with 
sepsis (nonsevere) and 17 patients with severe sepsis, including septic shock. In the 
group of patients with severe sepsis, follow-up blood draws were taken according to 
the clinical follow-up assessment of the patient by the critical care team, which was 
based on organ-failure score SOFA. Follow-up blood draws were initiated if the 
patient recovered to a SOFA score of less than 3 points or did not show improvement 
from initial SOFA score after 2 weeks. An earlier follow-up blood draw was initiated if 
the patient showed a rapid clinical deterioration. On average, follow-up reads were 
taken 7 days after admission. Seventeen control patients with noninfectious medical 
conditions (see also Table 5). Control patients had to have at least two permanent 
medical conditions requiring medical therapy and were matched by age to the 
severe-sepsis cohort. The study was approved by the local ethics committee of the 
University of Munich in accordance with the Declaration of Helsinki.  
 
2.2.6 Platelet and bacterial interaction studies  
The bacteria mentioned under 2.1.4 were used and analyzed. The bacteria were 
stored at -80°C in glycerol stocks (1:2). 24 hours prior to each study, 2µl of the 
bacteria stock were expanded on LB media plates overnight at 37°C until they 
reached a stationary growth phase. LB medium contained 0.5% yeast extract, 1% 
tryptone and 1% NaCl, was adjusted to pH 7 and autoclaved. The next day some 
colonies were resuspended in PBS and their concentration was determined 
spectrophotometrical at a wavelength of 600nm. 
 OD600nm = 1 × 105bacteriaµl  
 
For each study, bacteria (4 x 106 total) were incubated in the presence of freshly-
isolated platelets (1 x 108) for four hours in M199 culture media. This incubation 
period provided an environment for exponential growth for the bacteria. To lyse the 
cells the platelet/bacteria mixture was pelleted at 600g for 2.5 minutes at RT and 
further treated as described under 2.2.7 or 2.2.8. 
 
2.2.7 Protein solubilisation for western blot analysis 
HMEC protein solubilisation: 
To obtain protein lysates for western blot analysis (wb) the HMEC were washed with 
cold PBS and ice-cold Cell Signaling lysis buffer containing an additional protease 
inhibitor 1mM phenylmethanesulfonylfluoride (PMSF) was added. The dishes were 
frozen for at least 20 minutes at -20°C and thawed on ice before scrapping off the 
cells. The cell suspension was transferred to a 1.5ml micro tube and for a mechanical 
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lysis the cells were passed through a small needle a few times. To lyse the cells 
completely they were incubated on ice for 20 minutes and vortexed every 10 minutes. 
To remove cellular debris the lysate was centrifuged at 10000g for 10 minutes at 4°C. 
The supernatant was given to a new micro tube and could be stored at -20°C or used 
directly for protein quantification.  
 
HL-60 protein solubilisation: 
To obtain protein lysates for wb the HL-60 cells were pelleted, washed with cold PBS 
and ice-cold Cell Signaling lysis buffer containing 1mM PMSF was added. The cell 
suspension was transferred to a 1.5ml micro tube and incubated for at least 20 
minutes at -20°C before thawed on ice. For a mechanical lysis the cells were passed 
through a small needle a few times before lysing them completely on ice for 20 
minutes and vortexing them every 10 minutes. To remove cellular debris the lysate 
was centrifuged at 10000g for 10 minutes at 4°C. The supernatant was given to a 
new micro tube and could be stored at -20°C or used directly for protein 
quantification. 
 
Platelet protein solubilisation: 
After adding the Cell Signaling lysis buffer containing 1mM PMSF the cell suspension 
was lysed on ice for 20 minutes and vortexed every 10 minutes. To remove cellular 
debris the lysate was centrifuged at 10000g for 5 minutes at 4°C. The supernatant 
was given to a new micro tube and could be stored at -20°C or used directly for 
protein quantification. 
 
2.2.8 Protein solubilisation for proteasome activity measurements 
HMEC protein solubilisation: 
To obtain protein lysates for wb the HMEC were washed with cold PBS and freshly 
prepared and ice-cold proteasome activity lysis buffer containing 20mM HEPES (pH 
7.5), 1mM MgCl2, 150mM NaCl, 0.5mM EDTA, 1mM DTT and 1% Phosphatase 
Inhibitor Cocktail 2 was added. The dishes were frozen for at least 20 minutes at -
20°C and thawed on ice before scrapping off the cells. The cell suspension was 
transferred to a 1.5ml micro tube and for a mechanical lysis the cells were passed 
through a small needle a few times. To lyse the cells completely they were incubated 
on ice for 20 minutes and vortexed every 10 minutes. To measure the 26S 
proteasome activities the lysate had to be used right away. For measuring the 20S 
proteasome activities the lysate was used right away or stored at -80°C but could 
only be thawed once.  
 
HL-60 protein solubilisation: 
To obtain protein lysates for wb the HL-60 cells were pelleted, washed with cold PBS 
and ice-cold proteasome activity lysisbuffer was added. The cell suspension was 
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transferred to a 1.5ml micro tube and incubated for at least 20 minutes at -20°C 
before thawed on ice. For a mechanical lysis the cells were passed through a small 
needle a few times before lysing them completely on ice for 20 minutes and vortexing 
them every 10 minutes. To measure the 26S proteasome activities the lysate had to 
be used right away. For measuring the 20S proteasome activities the lysate was 
used right away or stored at -80°C but could only be thawed once. 
 
Platelet protein solubilisation: 
After adding the proteasome activity lysisbuffer the cell suspension was lysed on ice 
for 20 minutes and vortexed every 10 minutes. To measure the 26S proteasome 
activities the lysate had to be used right away. For measuring the 20S proteasome 
activities the lysate was used right away or stored at -80°C but could only be thawed 
once. 
 
2.2.9 Protein quantification  
Protein quantification was determined using the bicinchoninic acid assay (BCA) Kit. 
The BCA is a two-step colorimetric assay [175, 176]. The first step involves the 
reduction of Cu2+ to Cu1+ by protein in an alkaline medium. This is the well-known 
biuret reaction. In the second step a purple-colored reaction product results from the 
salt of the BCA chelating the reduced cuprous cation. The BCA/copper complex 
exhibits a strong linear absorbance at 562nm with increasing protein concentrations.  
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All cell lysates were analysed accordingly. The necessary amount of BCA reaction 
reagents A and B was mixed for one minute (50:1). In a 96-well plate 10μl of the 
protein standard albumin or samples were added in duplicates on ice. To each well 
200μl of the mixed reaction reagents was added. The reaction took place while 
incubating the plate at 37°C for 30 minutes. The absorbance was measured at 
550nm on a plate reader and the concentrations were calculated using a standard 
curve (serial dilution of albumin, BSA). Using the following equation x was dissolved 
to receive the amount of protein in µg.  
 y = mx + b 
 
Where y is the measured absorbance, m is the gradient of the standard curve and b 
is the axis intercept of the standard curve.  
 
2.2.10 Gel electrophoresis and western blot analysis 
The western blot or immunoblot is a visualization of specific proteins. For this 
analytical method a protein solution needs to be separated first. Therefore proteins 
are separated according to their electrophoretic mobility, hence their molecular 
weight in SDS polyacrylamide gel electrophoresis [177]. This specific gel 
electrophoresis is called sodium dodecyl sulphate polyacrylamid gel electrophoresis 
(SDS-PAGE). Through ß-Mercaptoethanol and sodium dodecyl sulphate (SDS) 
proteins are denatured and applied with a negative charge. Denatured negatively-
charged proteins migrate across the gel to the direction of the anode under an 
applied electric field.  
Prepared or bought acrylamide gels were set in the electrophoresis apparatus which 
was filled up with running buffer consisting of 25mM Tris Base, 192mM glycine and 
0.1% SDS. The self-prepared SDS gels consisted of a 10% or 12% separation gel 
and a 4% stacking gel. For the mixture of the gels see section 2.1.6, whereupon 
TEMED and APS were added immediately before pouring and the top of the 
separation gel was covered with isopropanol while polymerizing. 20µg up to 60µg 
protein, depending on the experiment and antibody (see section 2.1.7), were mixed 
with 4x loading buffer containing 0.25M Tris pH 6.8, 8% SDS, 40% glycerol, 0.02% 
bromophenol blue and 400mM ß-Mercaptoethanol and heated for 5min at 95°C. This 
denatured protein was loaded on the gel next to 5µl of a protein ladder. Through 
Bromophenol blue the loading front of the samples was visible in the gel. 
Gel electrophoresis was performed at 100V in an electrophoresis apparatus by 
Peqlab for about 15 minutes until the loading front entered the separation gel. After 
the samples had passed the stacking gel electrophoresis was performed at 150V for 
about 40min (depending on the size of proteins).  
To preserve the protein bands they were transferred to a polyvinylidene difluoride 
membrane (PVDF) before they could be detected using antibodies. The PVDF 
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membrane needed to be pre-wetted in methanol due to its hydrophobicity before it 
could be used with the aqueous freshly-prepared transfer buffer containing 25mM 
Tris Base, 200mM glycine and 20% methanol. 
For blotting a wet electroblotting system was used. In between two sponges there 
were two sheets of Whatman filter paper, a membrane, the gel, and again two sheets 
of filter paper. This sandwich was prepared without any air bubbles and put in the 
transfer buffer-filled apparatus (the membrane facing the anode). In an electrical field 
for 2h at 55V the proteins were able to migrate to the membrane surface. All 
transferred protein bands could be visualized by staining with Ponceau S which binds 
reversible to amine groups of proteins. Staining occurred in 0.1% Ponceau S in 5% 
acetic acid for 10 minutes at RT and the stain was removed by continued washing in 
distilled water. 
Finally specific proteins could be detected using specific primary and secondary 
antibodies (as indicated under sections 2.1.7 and 2.1.8) where the primary antibody 
binds to a specific protein on the membrane and the HRP-conjugated secondary 
antibody detects the heavy chain of the primary antibody. Addition of hydrogen 
peroxide and luminol or another chemiluminescent substrate gives a luminescence 
which is detected.  
In the beginning the membrane was incubated for 1h in blocking solution (5% BSA or 
powdered milk in 1x TBS-T) at RT. TBST is a buffer consisting of 50mM Tris Base, 
150mM NaCl and 0.1% Tween. Blocking excludes unspecific binding on protein free 
spots of the membrane. Incubation of the primary antibody was performed as 
composed in the antibody list under gentle shaking at 4°C overnight (2.1.7). After 
washing the membrane trice for 10min in TBS-T the incubation with the secondary 
antibody conjugated to horseradish peroxidase (HRP) took place for 1h at RT. 
Unbound secondary antibodies were removed by washing (3x). The protein bands 
were detected by adding a solution containing 0.1M Tris Base pH 8.5, 0.4mM p-
coumaric acid, 2.5mM Luminol and 0.08% H2O2 (30%). Hereby is coumaric acid an 
enhancer of the reaction and H2O2 was added last because it starts the reaction. The 
membrane was developed for 20 up to 180 seconds in an imager from Hamamatsu 
(depending on the antibody). 
 
 
 
 
More than one protein could be detected with one membrane. After an experiment 
the membrane was stored at -80°C. Density measurement was performed with the 
area analysis of Hokawo from Hamamatsu Photonics, Japan. 
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2.2.11 Proteasome activity measurements 
Measurement of the chymotrypsin-like activity of the 20S proteasome using 
APT280 Millipore Kit 
The Millipore Kit is based on the LLVY-AMC (7-amino-4-methylcoumarin) substrate 
that was used in many publications, such as Conconi et al. [178] or Pacifici et al. 
[179]. An intact proteasome is able to cleave the peptide LLVY from the fluorophor 
AMC with its chymotrypsin-like activity and the free AMC can be quantified using a 
fluorometer. Here AMC was excited at 360nm and emission at 460nm was detected.  
The assay was performed as described by the manufacturer. 1x108 washed platelets 
were lysed as described under 2.2.8 in a lysis buffer containing (150mM NaCl, 50mM 
HEPES (pH 7.5), 5mM EDTA, and 1%Triton-X 100). 10-20μl of lysed cell suspension 
was given to a black 96-well plate containing 1x assay buffer and 25μM of the 
substrate. Samples were measured in triplicates and standards in duplicates. Then 
either the kinetic for 2 hours every 15 minutes at 37°C was analyzed by detecting the 
emission at 460nm in a fluorometer or the end amount of AMC was detected after 
incubation in the dark at 37°C for 2h. Fluorescence units (FU) were detected and 20S 
chymotrypsin-like activitiy of the 20S proteasome is given as FU relative to the total 
amount of protein of each sample. 
 CT − L activity of the 20S proteasome =  FUµg of protein 
 
Therefore a protein quantification of each sample was performed for each 
experiment. To make sure the assay was functioning correctly a positive control 
provided by the manufacturer and an AMC standard curve was analyzed during each 
run.  
 
Measurement of all six activities of the proteasome in cell lysates 
As described under section 1.3.1 the multicatalytic enzyme, proteasome, possesses 
six activities; the chymotrypsin-like (CT-L), the trypsin-like (T-L), and the caspase-like 
(C-L) activity of the 26S proteasome and the same three of the 20S proteasome. 
With different peptides coupled to a flourophor it is possible to assess the CT-L, T-L 
or C-L activities and by changing the assay buffer one is able to measure either the 
activities of the 26S proteasome complex (dependent on ATP) or of the 20S 
proteasome complex (see also section 1.3.1). Activities were assayed according to 
modified published protocols [180, 181] and as described by Drews et al. 2010 [182].  
 
Lysates were generated as described in section 2.2.8 with a freshly prepared 
proteasome lysis buffer containing 20mM HEPES (pH 7.5), 1mM MgCl2, 150mM 
NaCl, 0.5mM EDTA, 1mM DTT, and 1% phosphatase inhibitor. Lysates were used 
directly after preparation to analyse all three activities of the 26S proteasome 
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complex, since this complex breaks down after freezing and then the activity will be 
significantly reduced.  
For each 26S proteasome activity assay 10μg protein of each sample is used 
consequently a protein quantification was performed before measuring the 
proteasome activities. In order to always have the same sample amount for each 
assay each lysate was adjusted to a solution containing 1μg/μl protein. The assay 
was performed in a black 96-well plate with a total volume of 100μl per well.  
All three 26S activities were measured in 20mM HEPES (pH 7.5), 1mM MgCl2, 
150mM NaCl, 0.5mM EDTA, 1mM DTT, and 50μM ATP [182]. Rapidly after adding 
0.1mM of the appropriate peptide substrate the plate was analyzed for 2h at 37°C 
measuring the emission of free AMC every 15min at 460nm in a fluorometer. To 
measure the CT-L activity of the 26S proteasome the Suc-LLVY-AMC substrate was 
used; the T-L activity was measured by the Boc-LSTR-AMC; and the C-L activity was 
analyzed using the Z-LLE-AMC. All samples were analysed in triplicates for each 
substrate and standards were run in duplicates. To assure that each well could be 
compared the end volume of each well contained 2% of DMSO (since inhibitors and 
substrates were solubilised in DMSO). To calculate the rate of activity an AMC 
standard curve was run for each experiment. Also to assure correct functionality a 
positive control was analyzed each time containing a purified proteasome.  
The measurement of the activities is given as enzyme turnover rate. The mean 
gradient of each sample was calculated and adjusted to the AMC produced per 
minute, and protein used. The rate is given in pmol x mg-1 x min-1.  
 Proteasome activity =  gradientgradient of standard curve  × 100 
 
The number 100 is based on 10µg of used protein converted to mg.  
All three activities of the 20S proteasome complex were measured on one day but 
not necessarily the same day as the activities of the 26S proteasome complex were 
detected. The 20S proteasome complex is still intact after one freezing step. The 
measurement of the activities of the 20S proteasome complex was performed in the 
same way as the measurement of the activities of the 26S proteasome complex but 
the assay buffer varied. The CT-L activity of the 20S proteasome complex was 
detected in 25mM HEPES (pH 7.5), 0.5mM EDTA, and 0.03% SDS [182]. The T-L 
and C-L activities of the 20S proteasome complex were analyzed in 25mM HEPES 
(pH 7.5), 0.5mM EDTA, 0.05% NP-40, and 0.001% SDS [182]. Again samples were 
measured in triplicates for each substrate and the activities of the 20S proteasome 
complex were calculated in the same way as the activities of the 26S proteasome 
complex and are given in pmol x mg-1 x min-1. 
All six activities were compared and could have been compared when performed with 
the same lysates.  
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2.2.12 Fluorescence activated cell sorting 
The Fluorescence Activated Cell Sorter (FACS) is able to carry out flow cytometry of 
cells at single cell level and cell sorting depending on the given model. For this cells 
are guided through a laser beam by hydrodynamic-focusing whereas parameters as 
forward scatter, side scatter and fluorescence can be detected. Each particle passing 
through the beam scatters the beam and fluorescent chemicals found in the cell or 
attached to the cell may be excited into emitting light. The forward scatter is a degree 
for the absorbed light and provides information about the cell dimensions; the side 
scatter indicates the reflected light and is therefore a measurement of the relative 
optical density which is proportional to the granularity of a cell. Through band-pass 
filters it is possible to detect emission spectra of various fluorescent dyes. Prior 
sorting the cells need to be treated with those dyes. 
Analysis was performed using a FACS Canto II flow cytometer with two lasers. The 
data generated here is shown in histograms, in a single dimension, or in two-
dimensional dot plots where every dot represents one cell. The histogram represents 
the cell count on the y-axis and the desired light intensity on the x-axis. To analyze 
the data in further detail the FACSDiva software was used during this work.  
Here the FACS was used to measure the mitochondrial membrane potential in 
platelets.  
 
To measure the mitochondrial membrane potential (Mmp) 5,5’,6,6’-tetrachloro-
1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide (JC-1 dye) was used. JC-1 is a 
lipophilic cationic dye that can penetrate living cells [183-185]. In healthy cells 
positively charged JC-1 can enter the negatively charged mitochondria and 
accumulates there [184]. In apoptotic cells when the Mmp drops JC-1 is located in 
the cytosol as monomers. JC-1 aggregates fluoresce red-orange and the monomeric 
form is green. Healthy cells are bright orange and green, whereas apoptotic cells lose 
their brightness and only have green fluorescence.  
5x106 isolated platelets were incubated with 1x JC-1 in platelet buffer in a volume of 
200μl for 20 minutes at RT in the dark in 5ml polysterene tubes. After adding 1ml of 
platelet buffer the samples were analyzed directly. They could not be stored.  
Mmp was assessed as a ratio of the median red fluorescence and green 
fluorescence, as used in previous publications as well [186]. Here this ratio is called 
Mmp-Index. A decrease in the red-to-green fluorescence ratio (Mmp-Index) 
represents a loss in mitochondrial membrane potential (depolarization). Mmp-Index 
was calculated as the mean of triplicate readings for each patient or donor. To assure 
correct function of the assay in each experiment not only measurements of platelets 
from a healthy donor but also an internal positive control was used in each 
experiment. Therefore prior to JC-1 staining one sample from the healthy donor and 
one sample from the patient was stimulated with 10μM calcium ionophore A23187 for 
10 minutes at 37°C which induced platelet apoptosis and rapid mitochondrial 
membrane depolarization [50].  
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    Mmp − Index =  red �luorescencegreen �luorescence 
 
2.2.13 Aggregometry 
A classical platelet function test is aggregometry. Hereby the ability of various agonist 
on platelets to induce platelet activation and aggregation is analysed in vitro. Platelet 
aggregation can be assessed by light transmission aggregometry, LTA, also called 
Born aggregometry or through impedance aggregometry, IA [33]. During LTA light 
transmission is detected by a photocell that sits behind a cuvette. While platelets 
aggregate, less light is absorbed and the transmission increases. During IA electrical 
impedance in whole blood is measured with two sensor electrodes. When platelets 
aggregate they adhere on the metal wire and increase electrical resistance.  
Born aggregometry was measured in PRP with the Aggregometer 490-2D. 400μl of 
freshly isolated PRP was given to a glas cuvette containing a small stirrer and hold 
on 37°C prior to use. PPP of the same donor was used as reference. The 
measurement was started by adding the agonist. Aggregation was measured 7-15 
minutes depending on the agonist under constant stirring (1200rpm). Aggregation is 
shown here in percent change of light transmission whereas 100% refers to 
transmittance through reference, or aggregation is given in area under the curve 
whereas better aggregating samples had a higher area under the curve.  
Aggregation in whole blood was performed using a Muliplate® Analyzer. Blood was 
drawn in tubes containing r-hirudin (0.045 mg/ml). 300μl whole blood was added to a 
test cell containing 300μl of saline. The measurement was started by adding an 
agonist and performed under 37°C for 6 minutes. Samples were measured in 
triplicates. The increase in impedance/aggregation is given in mean arbitrary units 
(AU). 
 
2.2.14 p65 transcription factor assay kit 
The transcription factor NFκB (p65) binds directly to DNA sequences when its 
inhibitor IκB is degraded. This active NFκB has been measured for many years. The 
p65 transcription factor assay from Abnova detects active NFκB by an enzyme-linked 
immunosorbent assay (ELISA). A 96-well plate is coated with a specific double 
stranded DNA (dsDNA) sequence containing the NFκB response element. Active 
NFκB in the samples binds to the dsDNA and is detected by a primary antibody 
directed against NFκB. Through a secondary antibody conjugated to HRP bound 
NFκB can be quantified photometrically. Normally 3,3’,5,5’-tetramethylbenzidine 
(TMB) is used as a HRP substrate (but manufacturers do not state the exact 
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substrate used). The oxidised TMB is blue but not stable. By adding nitric acid a 
yellow product is generated which is stable and can be measured at 450nm. 
Nucleated cells contain active NFκB in the nucleus and therefore an isolation of 
nuclei prior to lysis is necessary. The anucleate platelets not only express NFκB as 
well but it seems to be active [70, 79, 80].  
Here 1 x 108 platelets were lysed according to section 2.2.7 but with a specific NFκB 
lysis buffer. A lysis buffer containing 200mM HEPES (pH 7.9), 400mM NaCl, 1mM 
EDTA, 1mM DTT, and 10% protease inhibitor cocktail was used to stabilze NFκB in 
the best way possible. 20µl of each platelet lysate were given to wells of a coated 96-
well plate containing a specific assay buffer provided by manufacturer (100µl total 
volume in each well). Samples were detected in duplicates. To let binding occur the 
plate was incubated at 4°C over night without agitation. After washing the wells 5x 
with manufacturer’s washing buffer the plate was incubated for 1h at RT with the 
primary antibody without agitation and in a second step with the secondary antibody. 
Prior to measuring the absorbance at 450nm photometrical the developing solution 
was added, the plate was incubated for 45min at RT and stopping solution was 
added. To assure the functionality of the assay a positive and negative control 
provided by manufacturer was analyzed in duplicates for each experiment.  
Bound NFκB, meaning active NFκB, is given in activity/µg total protein. Therefore 
protein quantification was performed for each experiment.  
 
2.2.15 MHC I peptide analysis 
MHC I peptide analysis was done in cooperation with Professor Stefan Stevanovic, 
University of Tuebingen, Germany. 
1 x 109 platelets were isolated and a pellet was send to Tuebingen. MHC I-presented 
peptides were obtained by standard immunoaffinity purification of MHC I molecules 
from platelets using the panHLA class I specific antibody W6/32 [187, 188]. HLA 
(human leukocyte antigen) ligands were analyzed by LC-MS/MS. Peptide samples 
were separated by reversed-phase liquid chromatography and subsequently 
analyzed in an on/line coupled LTQ Orbitrap-XL hybrid mass spectrometer. Eluting 
peptides were ionized by nanospray ionozation and analyzed in the mass 
spectrometer implementing a top 5 CID (collision induced dissociation) method. For 
data processing, the software Proteome Discoverer was used to integrate the search 
results of the Mascot search engine against the human proteome as comprised in the 
Swiss-Prot database [189]. 
 
2.2.16 Statistical analysis 
Statistical analysis was performed with SigmaPlot 10.0. Data are presented as 
arithmetic means +SEM. Statistical analysis was performed using a T-test for 
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unpaired data or ANOVAs when necessary. A p-value less than 0.05 is considered 
significant. For each result the specific test is named and the p-value is given under 
figure explanations. 
Statistical analysis concerning results of patients was performed with SigmaPlot 10.0 
along with SAS 9.3 for Unix and Linux. Patient characteristics, clinical scores, Mmp-
Index, and proteasome acitivity values are given as median and interquartile range. 
Correlations of platelet Mmp-Index and clinical disease scores (APACHE II, SOFA, 
SAPS II) were calculated by using Spearman rank correlation coefficients. Here 
again for each result the specific T-test or ANOVA is named under figure 
explanations.  
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3 Results 
 
3.1 Characterization of the proteasome in human 
platelets 
For some years it is known that anucleate platelets express subunits of the 
proteasome [159-161]. Klockenbusch et al. [63] only recently (2014) identified all 
proteasome subunits in human platelets by a global proteome analysis. The 
proteasome has several catalytic activities [160] and can be regulated in response to 
an agonist stimulation [163]. But further research is necessary to have detailed 
knowledge of the proteasome with all its activities and its regulation in human 
platelets. 
 
3.1.1 Human platelets express proteasome subunits 
In order to confirm the expression of three subunits of the proteasome complex their 
protein levels in non-stimulated platelets was analyzed and quantitatively compared 
to those in nucleated cells. PSMA3, a subunit of the 20S core protein, PSMC5, a 
subunit of the 19S regulator, and PSME1, a subunit of the 11S regulator, are shown 
in Figure 9. 
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Figure 9: Expression of PSMA3, PSMC5 and PSME1 in human platelets compared to nucleated 
cells. Representative western blot images of the PSMA3, PSMC5 and PSME1 proteins and the 
loading control β-actin are illustrated of nucleated HMEC and HL-60 cells, as well as of platelets (plt). 
Lower panel: Proteasome subunit expression was quantified by band densitometry analysis with the 
help of a protein to actin ratio. Mean protein to actin ratio for the HMEC cells was set as 1 and the 
relative expression in HL-60 cells and platelets is seen (Kruskal-Wallis one-way analysis of variance; 
PSMA3: *p<0.005, n=6; PSMC5, PSME1: *p<0.003, n=5). 
 
All three subunits of the proteasome, PSMA3, PSMC5, PSME1, are expressed in 
detectable levels in human platelets (Figure 9). Compared to the nucleated cells HL-
60 and HMEC platelets express significantly less amount of these protein subunits. 
PSMA3 is 2.28±0.06-fold higher expressed in HMEC cells compared to platelets, 
PSMC5 is 2.33±0.10-fold higher expressed and PSME1 is 1.79±0.10-fold higher 
expressed in HMEC cells compared to platelets.  
 
3.1.2 Human platelets contain an active proteasome 
Further it is to be analyzed if the proteasome is active. Therefore the chymotrypsin-
like (CT-L) activity of the 20S proteasome in human platelets was detected using the 
20S Proteasome Activity Assay from Millipore. The kit is based on the fluorogenic 
peptide substrate LLVY-AMC (see section 2.2.11).  
 
Detection and inhibition of the chymotrypsin-like activity of the 20S 
proteasome 
After in vitro incubation of human platelets with the known proteasome inhibitors 
epoxomicin and lactacystin the 20S proteasome activity was tested. Epoxomicin 
belongs to the class of α’,β’-epoxyketones and is highly specific for the proteasome 
[140]. The proteasome inhibitor lactacystin belongs to the class of β-lactones and is 
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less specific because it inhibits other proteases others than the proteasome as well 
[139] and it restrains the proteasome activity at a slower rate than epoxomicin [140]. 
 
Figure 10: Chymotrypsin-like activity of the 20S proteasome in human platelets. 20S 
chymotrypsin-like (CT-L) activity was detected by a kit using LLVY-AMC as a substrate. A: The kinetic 
of the 20S CT-L activity in platelets was detected every 15min over a 2h time course. Resting platelets 
after 10min (ctr=control) and platelets treated with 1µM epoxomicin (epox) or 25µM lactacystin (lacta) 
for 10min are seen. B: Activity after 2h of treated lysates is shown relative to resting platelets after 
10min (control) (Kruskal-Wallis one-way analysis of variance, *p<0.005, n=6, lacta: n=3). C: DMSO 
does not affect the 20S CT-L proteasome activity. Activity after 2h of DMSO treated cells is shown 
relative to resting platelets after indicated time points (ctr). Platelets were incubated with 0.2%, 0.1% 
or 0.01% dimethyl sulfoxide (DMSO) (Kruskal-Wallis one-way analysis of variance, n=4). 
 
The flourogenic substrate was given to platelet lysates and fluorescence was 
detected every 15 minutes for 2 hours. The measured fluorescence units relative to 
the protein amount used are pictured (Figure 10A) or fluorescence units after 2 hours 
were normalized to resting platelets in vitro incubated for 10 minutes (here indicated 
as control, Figure 10B). Figure 10 shows that the 20S CT-L activity is detectable. 
Additionally the activity is significantly inhibited up to 85% (±5%) when platelets are 
incubated in vitro with 1µM of the specific proteasome inhibitor epoxomicin before 
lysis. In our experiments a reduction in the 20S CT-L activity by 62% (±18%) could be 
seen by incubation with lactacystin. This is not as effective as epoxomicin. Dimethyl 
sulfoxide (DMSO) is a common solvent to dissolve nonpolar and polar compounds 
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and does not have a significant influence on proteasome activity (Figure 10C). 
Concentrations of DMSO were tested at different time points (0.2%, 0.1% and 0.01% 
DMSO were given to platelets for either 10min, 1h or 3h).  
 
Age dependency of 20S CT-L proteasome activity in platelets 
In many tissues during ageing misfolded proteins are known to accumulate as a 
result of a declining proteasome activity [190]. Hence, aged platelets assessed by 
storing platelet concentrates for 8 days were analyzed according to their proteasome 
activity.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: 20S CT-L activity in human platelet concentrates. A: Using the Millipore kit the 20S CT-
L activity after 2h was measured. Platelet concentrates are depicted in FU/µg (n=2). B: Platelet 
aggregation of platelet concentrates was performed by Born aggregometry using 3µg/ml collagen for 
stimulation (n=2). 
 
To analyze if the proteasome activity is age dependent we further tested the 20S CT-
L activity in platelet concentrates over a time course of several days. As seen in 
Figure 11A platelet concentrates measured over 8 days show a decrease in 20S CT-
L proteasome activity (3.63±0.42FU/µg day 0, 1.83±1.41FU/µg day 8). Furthermore a 
reduction in collagen-induced aggregation of platelet concentrates over 8 days is 
shown here (278.33±22.98Units day 0, 8.05±8.05Units day8, Figure 11B). Overall 
Figure 11 indicates age-dependent decrease in proteasome activity in human 
platelets. Supporting this data we observed a lower 20S CT-L activity in a small 
cohort of elderly donors with an average age of 63 years compared to young donors 
with an average age of 28 years. 
 
3.1.3 26S and 20S proteasome complexes are active on all three 
catalytic activities 
The kit used here only detects the 20S CT-L activity but the proteasome possesses 
three catalytic activities (as described in section 1.3.1 and 2.2.11). A method to 
measure all three catalytic activities of the 26S and 20S proteasome in platelets was 
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established in our laboratory. The 26S proteasome is ATP dependent and an 
addition of ATP to the assay buffer is obligatory. The three catalytic activities were 
measured with the fluorogenic peptide substrates mentioned under 2.1.9.  
 
Comparison of all three catalytic 26S and 20S proteasome activities in human 
platelets and nucleated cells 
Initially we looked at all 26S activities and 20S activities of the proteasome in 
platelets and at those activities of the proteasome in nucleated cells, the endothelial 
cell line HMEC and the leukaemia cell line HL-60.  
 
 
Figure 12: 26S and 20S proteasome activities of platelets, HMEC and HL-60 cells. A: The 26S 
and 20S chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) proteasome activities of 
platelets, HMEC and HL-60 cells were detected by fluorogenic substrates. B: A detailed view on the 
proteasome activities of platelets from panel A is given (Kruskal-Wallis one-way analysis of variance, 
*p<0.05 versus the respective activity of HMEC cells, n=6). 
 
Activities are represented in pmol AMC produced relative to the amount of protein 
used over time. All activities of the 26S proteasome and 20S proteasome in human 
platelets were detectable levels but the 26S proteasome activities in platelets are 
significantly smaller compared to respective activities in nucleated cells (Figure 12A). 
The 26S CT-L activity in platelets is 21.38±4.93pmol/(mg*min) whereas the 26S CT-L 
activity in HMEC cells is 430.8 pmol/(mg*min). All exact activities are mentioned in 
Table 3. For a better resolution all proteasome activities of human platelets are 
pictured (Figure 12B). 26S proteasome activities in platelets show a rate of 
21.38±4.93, 4.08±0.77 and 10.88±3.47pmol/(mg*min) (CT-L, T-L and C-L 
respectively) while 20S proteasome activities reach 215.99±33.54, 368.51±34.35 and 
234.43±33.09pmol/(mg*min). 
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Cell type 26S proteasome activities 
[pmol/(mg*min)] 
20S proteasome activities 
[pmol/(mg*min)] 
Platelets CT-L     21.38±4.93 CT-L    215.99±33.54 
T-L       4.08±0.77 T-L     368.51±34.35 
C-L      10.88±3.47 C-L     234.43±33.09 
HMEC CT-L    430.76±68.24 CT-L    254.69±110.23 
T-L     289.52±69.69 T-L     588.00± 67.95 
C-L     123.37±71.18 C-L     493.58±103.68 
HL-60 CT-L    315.89±71.96 CT-L    128.83±41.32 
T-L     108.07±17.36 T-L     505.03±79.25 
C-L      55.76±12.55 C-L     397.27±38.02 
Table 3: 26S and 20S proteasome activities in platelets, HMEC ,and HL-60 cells. 
 
Specificity of the established proteasome activity assay 
From all proteases in platelets the proteasome is a unique type of protease and plays 
an important role not only for protein degradation but also for regulation of cellular 
processes (see section 1.3). The used peptide substrates are specific for 
measurements of proteasome activity and they are not cleaved by other proteases. 
Peptides are coupled to the fluorophor AMC which has a high fluorescence (emission 
at 460nm) and therefore is mostly used to measure proteasome activity [191]. Many 
peptide substrates exist but LLVY, LSTR, LLE were used here as described by 
others [112, 140, 159, 191]. The influence of platelet proteases others than the 
proteasome (e.g., cathepsins, calpain, papain, trypsin, and chymotrypsin) on the 
fluorogenic peptide substrates was investigated by adding specific proteasome 
inhibitors to the assay (after lysis). 10µM epoxomicin was used to inhibit the CT-L 
and T-L proteasome activities and 30µM Z-Pro-Nle-Asp-CHO was used for the C-L 
proteasome activities [182]. Epoxomicin belongs to the class of α’,β’-epoxyketones 
and is a highly specific proteasome inhibitor for the CT-L and T-L activities [140]. 
Epoxomicin most potently inhibits the 20S CT-L activity at a concentration of 1µM 
and the 20S T-L activity is inhibited at a concentration of 10µM [140]. Effects of 
inhibitors on the 26S proteasome (the 20S core particle with its 19S regulatory 
particle) has not been analyzed in detail. Z-Pro-Nle-Asp-CHO is an aldehyde based 
inhibitor and is known to have an inhibitory concentration of 30µM for the 20S C-L 
proteasome activity [182, 192], again its specificity for the 26S proteasome is not 
described in detail. 
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Figure 13: The established assay is specific to detect proteasome activity in platelets. The 26S 
(A) and 20S (B) chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) proteasome 
activities were analyzed and compared to lysates incubated with 10µM epoxomicin (epox) or 30µg Z-
Pro-Nle-Asp-CHO (PND) for 15min (Mann-Whitney rank sum test, *p<0.03 versus control, n=5). 
 
The CT-L, T-L, C-L activities are all effectively inhibited after incubating lysates with 
proteasome inhibitors compared to resting platelets (26S activities: 81±5% inhibition, 
48±11% and 62±4%; 20S activities: 100±0.02% inhibition, 86±1%, 92±0.05%; Figure 
13). Interestingly, Figure 13A shows that the 26S activities of platelets are effectively 
inhibited but not as effectively as the 20S activities. For that reason it can be 
concluded that the fluorogenic peptide substrates used here are highly specific for 
assessment of the 20S proteasome activities. 
 
3.1.4 The proteasome is differentially regulated in human platelets 
The discovery of the synthesis of the highly specific proteasome inhibitor epoxomicin, 
a natural product, was a breakthrough for proteasome inhibition. But until today the 
search for more sophisticated and effective inhibitors goes on. Here the effect of 
known proteasome inhibitors on all catalytic proteasome activities (CT-L, T-L, C-L) in 
human platelets is inspected. Furthermore, only few publications analyzed 
proteasome activation in human platelets. It is shown that the calcium ionophore 
A23187 stimulates the platelet 20S CT-L proteasome activity [163]. Here different 
potential agonists were tested in more detail on all activities of the 20S and 26S 
proteasome in human platelets. Regulations on all activities were not detectable. 
Therefore following graphs only show the enhanced activities by each agonist 
stimulation (Figure 15 and Figure 16). 
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Effects of known proteasome inhibitors on all 26S and 20S activities 
Platelets treated with specific proteasome inhibitors before lysis were analyzed. 
Reduction of all proteasome activities of different inhibitors (epoxomicin, bortezomib 
and lactacystin) is demonstrated (Figure 14).  
 
 
 
Figure 14: Inhibition of the 20S and 26S proteasome activities in human platelets. The 26S (A) 
and 20S (B) chymotrypsin-like (CT-L), trypsin-like (T-L) and caspase-like (C-L) proteasome activities 
of treated platelets are shown relative to resting platelets after 30min (control). Platelets were handled 
with 10µM epoxomicin (epox), 10µM bortezomib (borte) or 30µg lactacystin (lacta) for 30min (Kruskal-
Wallis one-way analysis of variance, *p<0.03 versus control, n=4). 
 
Figure 14A illustrates the 26S proteasome activities and Figure 14B the 20S 
proteasome activities. It is seen that both CT-L activities are significantly inhibited by 
10µM epoxomocin, 10µM bortezomib and 30µM lactacystin (26S: with epoxomicin 
96±2% reduction of activity, with bortezomib 92±6% reduction of activity, with 
lactacystin 83±9% reduction of activity; 20S: with epoxomicin 100±0.08% reduction of 
activity, with bortezomib 96±1% reduction of activity, with lactacystin 90±2% 
reduction of activity). The 26S C-L proteasome activity is restrained 78±6% by 10µM 
epoxomicin and significantly 82±7% by bortezomib, while the 20S C-L activity is 
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significantly inhibited by all three inhibitors (epoxomicin: 80±4%, bortezomib: 97±1%, 
lactacystin: 64±12%). The T-L activities are not significantly inhibited with epoxomicin 
or lactacystin and bortezomib does not restrict the T-L activities at all (Figure 14). 
These three specific proteasome inhibitors are known to have different inhibitory 
concentrations for each activity.  
 
Calcium ionophores activate 26S proteasome activities 
First the calcium ionophores A23187 and ionomycin were examined on all activities 
of the 20S and 26S proteasome complexes. Secondly, polyubiquitinated proteins 
were measured. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Calcium ionophores increase the 26S CT-L and T-L activities of the platelet 
proteasome leading to enhanced degradation of polyubiquitinated proteins. Measured 26S CT-L 
proteasome activity (A) and T-L proteasome activity (B) of treated platelets are illustrated relative to 
resting platelets (ctr). Platelets were either treated with 2µM A23187 (A23) or 0.5µM ionomycin (iono) 
alone or they were preincubated with 1µM epoxomicin (epox) before adding the stimulants (Kruskal-
Wallis one-way analysis of variance, *p<0.004 versus control, #p<0.004 versus A23 or iono alone, n=7 
CT-L, n=4 T-L). C Western blot analysis of polyubiquitinated proteins after an in vitro incubation with 
proteasome inhibitors 1µM epoxomicin (epox) and 30µM lactacystin (lacta) for 7h or the proteasome 
activator 0.5µM ionomycin (iono) for 10min (n=4). 
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A23187 or ionomycin stimulation of platelets enhances the 26S CT-L activity 
significantly by 4.19±0.82-fold and 2.97±0.53-fold respectively (Figure 15A). With 
Figure 15B an increase of the 26S T-L activity is observed for the first time. The 26S 
T-L activity is increased by A23187 and ionomycin to 6.75±1.22-fold and 5.46±1.77-
fold respectively. Unique involvement of the proteasome complex was verified by 
preincubation with the proteasome inhibitor epoxomicin, which abrogated the 
upregulation of the activities. It comes to an inhibition similar to the one of epoxomicin 
alone (Figure 15A and B). Figure 15C shows the accumulation of polyubiquitinated 
proteins after proteasome inhibition whereas less polyubiquitinated proteins are 
detected after enhancing the proteasome activity by ionomycin. 
 
The platelet agonist collagen enhances 26S CT-L proteasome activity 
Proteasome activity is differentially regulated in platelets. Whether its activation plays 
a role in platelet activation/aggregation is not addressed in detail to date. As a 
consequence the influence of different platelet agonists on all proteasome activities 
was examined and collagen was found to regulate the proteasome activity. Figure 16 
clarifies that the platelet agonist collagen enhances the 26S CT-L activity in human 
platelets.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Collagen increases the 26S CT-L of the platelet proteasome. 26S CT-L proteasome 
activity was detected by a fluorogenic peptide substrate and is represented relative to resting platelets 
(ctr=control). Platelets were either incubated with 2µg/ml or 1µg/ml collagen alone for 7min or they 
were preincubated with 1µM epoxomicin (epox) for 15min before adding the stimulant (Kruskal-Wallis 
one-way analysis of variance, *p<0.001 versus control, #p<0.001 versus collagen alone, n=4). 
 
As visualized in Figure 16 the platelet agonist collagen significantly stimulates the 
26S CT-L activity of platelets to 1.72±0.08-fold when used in a concentration of 
1µg/ml. 2µg/ml collagen activates the 26S CT-L activity even to 1.99±0.29-fold. A 
proteasome inhibition efficiently reverses this enhancement (0.08±0.04-fold 1µg/ml 
collagen, 0.05±0.04-fold 2µg/ml collagen), which is an inhibition similar to the one of 
epoxomicin alone (0.04±0.03-fold). 
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3.1.5 Proteasome substrates 
The proteasome, as the major degradation system in eukaryotic cells, degrades 
proteins into peptides but over time the proteasome, more precisely the 
immunoproteasome, became known to generate peptides for cellular antigen 
presentation on major histocompatibility complex I (MHC I) [130, 131]. Additionally 
recent publications found out that the proteasome is able to cleave proteins into large 
functional fragments [150, 151]. The regulation and mechanism of this distinct 
proteolytic activity of the proteasome is not fully understood, yet. The following data 
illustrate the approach to identify proteasome substrates. 
 
MHC I peptide analysis 
In cooperation with Professor Stefan Stevanovic, University of Tübingen, MHC I 
complexes from platelet lysates were isolated and peptides presented on them were 
analyzed by mass spectrometry. Since 2012 it is known that platelets present 
antigens on MHC I complexes [58] and proteomic analysis already confirmed that 
anucleate platelets contain the protein machinery to process and present antigens to 
other cells [63]. Table 4 lists 10 representative proteins to which the peptides (HLA 
ligands) found on platelet MHC I belonged. The analysis was performed with one 
donor in two individual experiments and only peptides found in both experiments 
were considered. HLA ligands, the accession of the protein source, and descriptions 
are listed in Table 4. Ligands presented belong to proteins that are involved in 
translation or biochemical processes as glycolysis and lipid biosynthesis or signaling 
pathways as NO signaling. One quarter of ligands belong to cytoskeletal proteins. 
The cytoskeleton is indispensible for platelet morphology and function and the 
cytoskeletal proteins Filamin A and Talin-1 were not only identified as proteasome 
substrates in our study but recently Gupta et al. [150] mentioned them as proteasome 
substrates as well.  
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HLA ligand Protein source Accession Description 
ESAGGLIQTAR 
QAAGNAVKR 
KPKEADESL 
EVAPDVRLR 
RELETVREL 
SVALPAIMR 
LELLDHVLL 
RELETVRELL 
Talin-1  cytoskeleton Q9Y490 Cytoskeleton 
GEITGEVRm 
GEITGEVRM 
QPASFAVSL 
Filamin A cytoskeleton P21333 Cytoskeleton 
EAAAIIAQR Drebrin Q16643 Cytoskeleton 
AAVAAVAAR 
AVAAVAARR 
VAAVAARR 
Neutral alpha-glucosidase AB Q14697 Glycoprotein formation 
ETVKDFVAR 
ESFGVPKGR 
Diacylglycerol kinase delta Q16760 Lipid biosynthesis 
ESTGSIAKR Fructose-bisphosphate aldolase A P04075 Glycolysis 
GTSSVIVSR F-box/WD repeat-containing protein 11 Q9UKB1 Ubiquitination 
SAAGPVAAPR Lysosomal amino acid transporter 1 homolog Q6ZP29 Membrane transport 
EVVTGVIGQR 
REFLQNLDAL 
RYDNVTILF 
Guanylate cyclase soluble subunit beta-1 Q02153 NO signaling 
GEVTNDFVmL 
KFIDTTSKF 
DVIGVTKGK 
60S ribosomal protein L3 P39023 Translation 
Table 4: HLA class I ligands from platelet lysates.  
 
Cytoskeletal proteins are cleaved by the proteasome 
The platelet cytoskeleton is indispensible for platelet morphology and function. 
Therefore the here found cytoskeletal proteasome substrates Filamin A and Talin-1 
(through HLA ligand analysis, Table 4) were tested for cleavage under proteasome 
activation or inhibition. Protein expression was performed to confirm that they are 
proteasome substrates and to emphasize the importance of the proteasome.  
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Figure 17: Proteasomal cleavage of Filamin A and Talin-1. Western blot analysis was performed 
after proteasome activation of platelets with 2µM A23187 (A23 n=11), 0.5µM ionomycin (iono n=11) 
and 7µg/ml collagen (col n=4) or plateletal proteasome was inhibited with 1µM epoxomicin for 10min 
(epox n=3). Expression of Filamin A (A) and Talin-1 (B) is demonstrated. ß-actin was used as a 
loading control. Band densitometry analysis is graphed of Filamin A and Talin-1 blots showing cleaved 
to full length protein ratios where resting platelets (control) were set as 1 (A A23, Iono: Kruskal-Wallis 
one-way analysis of variance, *p<0.001 versus control; others: Mann-Whitney rank sum test, *p<0.001 
stimulus versus control). 
 
Filamin A cleavage can be observed by detecting a 225kDa Filamin A fragment via 
western blot and Talin-1 cleavage is detected by expression of a 190kDa fragment. A 
proteasome activity enhancement with calcium ionophores (A23187 or ionomycin) 
and collagen yield significantly more cleaved Filamin A 225kDa (Figure 17A) and 
more cleaved Talin-1 190kDa (Figure 17B) respectively compared to resting platelets 
(control). Control was set as 1 and Filamin A cleavage is 2.80±0.50-fold increased by 
A23187, 5.81±2.40-fold by ionomycin, and 3.53±1.73-fold by collagen. Talin-1 
cleavage is enhanced by 2.91±0.80-fold by A23187, 2.98±0.52-fold by ionomycin, 
and 4.68±0.67-fold by collagen. An inhibition of proteasome activity by epoxomicin 
shows less cleaved Filamin A (0.60±0.06-fold) and almost equally cleaved Talin-1 
compared to resting platelets (0.80±0.09-fold). Preincubation with epoxomicin prior to 
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proteasome activation depresses the cleavage of the proteasome substrates Filamin 
A and Talin-1 a little. Since those substrates can be cleaved by other enzymes as 
well a complete suppression of cleavage was not detected.  
 
3.2 Role of the proteasome in platelet function  
Slowly the role of the proteasome in platelets is approached but until today it is not 
well studied. Only recently it was indicated for the first time that a proteasome 
inhibition by MG132 or bortezomib reduces thrombin-induced aggregation and 
microparticle shedding [150]. But how an inhibition of aggregation exactly works had 
not been analyzed yet. Therefore cellular signaling pathways involving the platelet 
proteasome are of interest.  
 
3.2.1 Proteasome inhibition restrains platelet aggregation 
The proteasome inhibitor epoxomicin itself is not known to possess antiplatelet or 
prothrombotic activity. But wether proteasomal inhibition by epoxomicin alters platelet 
functions after agonist stimulation is not well studied until today. Here we 
demonstrate that a proteasome inhibition by epoxomicin affects aggregation 
stimulated with ADP or low concentrations of collagen.  
 
 
Figure 18: Aggregation stimulated with ADP or low concentrations of collagen is reduced by 
proteasome inhibition. A: Platelet aggregation in whole blood (WB) was performed by impedance 
aggregometry (Multiplate®) using 6.5µM ADP. Blood was either treated with 10µM epoxomicin (epox) 
or 10µM bortezomib (borte) for 10min (Kruskal-Wallis one-way analysis of variance, *p<0.001 versus 
control, n=5). B: Platelet aggregation in PRP was performed by Born aggregometry using 1-2.5µg/ml 
collagen. Illustrated is the area under the curve relative to a control. PRP was incubated with 200µM 
bortezomib (borte) and 5µM epoxomicin (epox) respectively for 10min (Kruskal-Wallis one-way 
analysis of variance, *p<0.001 versus control, #p<0.001 versus DMSO, n=8). C: Representative 
readings of the collagen-induced aggregation measurements (samples were analyzed in duplicates).  
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Figure 18A shows that proteasome inhibition decreases platelet aggregation 
stimulated with 6.5µM ADP in whole blood. Aggregation induced by low 
concentrations of collagen (1-2.5µg/ml) was measured in PRP. This way an effect of 
other blood cells can be excluded. Here aggregation is reduced as well by 
proteasome inhibitors (97±2% inhibition by 200µM bortezomib, and 45±7% inhibition 
by 5µM epoxomicin). Higher doses of agonists are able to overcome these 
reductions in aggregation. Representative aggregation traces measured by Born 
aggregometry stimulated with collagen are depicted in Figure 18C; decrease of 
aggregation by 5µM epoxomicin is illustrated.  
 
3.2.2 NFκB as a regulator of the proteasome in platelets 
The transcription factor NFκB is assumed to possess non-genomic functions. 
Analysis of non-genomic functions can elegantly be studied in anucleate platelets. In 
2009 Malaver et al. [70] published data demonstrating the existence of the NFκB 
pathway in anucleate platelets and its effect on platelet aggregation was discovered. 
NFκB inhibitors were found to diminish platelet aggregation [70, 83], similar to 
proteasome inhibitors (Figure 18). Furthermore, IκBα, the inhibitory protein of NFκB, 
is degraded by the proteasome. In this study a connection of NFκB and the 
proteasome was investigated.  
 
NFκB influences aggregation in human platelets 
NFκB is found in platelets and influences platelet aggregation. Here ADP- and 
collagen- induced aggregation was inspected. 
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Figure 19: Reduction of ADP- and collagen-induced aggregation in human platelets by NFκB 
inhibitors. A: Platelet aggregation in whole blood (WB) was performed by impedance aggregometry 
(Multiplate®) using 6.5µM ADP. Blood was incubated with 10µM NFκB inhibitors Ro 106-9920 (Ro) 
and Bay 11-7082 (Bay) for 1h (Kruskal-Wallis one-way analysis of variance, *p<0.001 versus control, 
n=5). B-D: Platelet aggregation in PRP was performed by Born aggregometry using 6.5µM ADP (B) or 
1-2.5µg/ml collagen (C,D). Illustrated is the area under the curve relative to a control. PRP was 
incubated as indicated with NFκB inhibitors Ro 106-9920 (Ro) and Bay 11-7082 (Bay) for 1h (Kruskal-
Wallis one-way analysis of variance, *p<0.001 versus control, B: n=6, C: n=5). D: Representative 
readings of the collagen-induced aggregation measurements (samples were analyzed in duplicates).  
 
Figure 19 confirms previous publications and pictures a reduction of ADP- and 
collagen-induced aggregation after inhibition of the NFκB pathway. Figure 19A shows 
that NFκB inhibition decreases platelet aggregation stimulated with ADP in whole 
blood. In PRP, to exclude an effect of other blood cells, aggregation is decreased as 
well (Figure 19B, 59±7% reduction in aggregation by 50µM Ro 106-9920, and 
65±13% reduction in aggregation by 50µM Bay 11-7082). When aggregation is 
stimulated with low concentrations of collagen (1-2.5µg/ml) aggregation is reduced by 
NFκB inhibition (51±12% inhibition by 50µM Ro, and 50±19% inhibition by 50µM 
Bay). Higher doses of collagen are able to overcome these reductions in 
aggregation. Representative aggregation traces measured by Born aggregometry 
stimulated with collagen are depicted in Figure 19D; decrease of aggregation by 
25µM Ro and Bay compared to a control). 
 
NFκB inhibitors prevent collagen-stimulated proteasome activity enhancement 
As demonstrated in Figure 16 collagen induces proteasome activity and collagen is a 
well studied platelet agonist leading to aggregation. Further the proteasome inhibitor 
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epoxomicin diminishes collagen-induced aggregation similar to NFκB inhibitors 
(Figure 18 and Figure 19). Thus to examine an interaction of the NFκB pathway and 
the proteasome on collagen-induced activation it was tested if not only epoxomicin 
reverses a collagen-stimulated increase of 26S CT-L activity but also NFκB inhibitors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: NFκB inhibitors prevent collagen-stimulated proteasome activation. Measured 26S 
CT-L proteasome activity of treated platelets is represented relative to resting platelets (ctr). Platelets 
were either treated with 1-2µg/ml collagen or NFκB inhibitors, 25µM Ro 106-9920 (Ro) and 25µM Bay 
11-7082 (Bay), alone or they were preincubated with NFκB inhibitors before adding the stimulant 
collagen (Kruskal-Wallis one-way analysis of variance, *p<0.001 versus control, #p<0.001 versus 
collagen alone, n=8). 
 
The collagen-induced boost in 26S CT-L activity is not seen by a preincubation with 
NFκB inhibitors (Figure 20). Platelets stimulated with collagen have a significant 
1.82±0.11-fold higher proteasome activity compared to resting platelets. Platelets 
incubated with NFκB inhibitors Ro and Bay alone do not have a significantly altered 
activity (0.74±0.11-fold for both). A preincubation with NFκB inhibitors even prohibits 
a collagen-induced increase of the 26S CT-L activity (0.57±0.11-fold and 0.64±0.10-
fold respectively significant versus 1.82-fold collagen). NFκB seems to play a role as 
a regulator of the proteasome in collagen-induced activation. 
 
NFκB activity is increased by collagen 
Since NFκB inhibitors prohibit collagen-induced aggregation, an activation of NFκB 
after collagen stimulation was studied. The proteasome inhibitor epoxomicin 
effectively inhibits NFκB activation as shown on HeLa cells [140]. NFκB is activated 
when its inhibitor IκBα is degraded leaving NFκB with its free nuclear localization 
signals (NLS). Those NLS can be detected even though non-genomic activity of 
NFκB is analyzed. 
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Figure 21: Collagen enhances NFκB activity in human platelets and increased proteasome 
substrate cleavage can be reversed by NFκB inhibitors. A: Through an NFκB transcription assay 
the NFκB activity is shown relative to resting platelets (ctr). Platelets were incubated with 25µM Bay 
11-7082, 10µM epoxomicin (epox) or collagen alone or a preincubation with 25µM Bay 11-7082 or 
10µM epoxomicin (epox) for 15min was performed before adding collagen for 7min (Mann-Whitney 
rank sum test, *p<0.02 versus control; Kruskal-Wallis one-way analysis of variance, #p<0.02 versus 
collagen alone, n=4). B: Platelets were incubated with collagen 7µg/ml or preincubated with NFκB 
inhibitors, 25µM Ro 106-9920 (Ro) or Bay 11-7082, for 10min (n=4). A representative western blot of 
the proteasome substrate Talin-1 is shown. ß-actin is used as a loading control.  
 
Active NFκB was measured in human platelets and Figure 21 demonstrates that 
there is not only the obvious efficient inhibition of NFκB by its inhibitor Bay (69%±7%) 
but there is an increase in NFκB activity by collagen (2.53±0.72-fold). This induction 
by collagen might not only be reversed by the NFκB inhibitor but also by the 
proteasome inhibitor epoxomicin (0.10±0.04-fold, 1.74±0.32-fold respectively). The 
proteasome substrate Talin-1 is not only cleaved after proteasome activation with 
calcium ionophores or collagen (Figure 17) but this cleavage can be reversed by 
epoxomicin. Demonstrated here in Figure 21 the enhanced cleavage is partly 
prevented with NFκB inhibitors as well.  
 
Collagen activates IκB kinase and promotes degradation of IκBα 
To confirm NFκB as a regulator of the proteasome, activation of IκB kinase (IKK) by 
collagen was tested. IKK starts the NFκB pathway by phosphorylating the inhibitory 
IκBα protein [76]. Further IκBα degradation under a collagen stimulus was analyzed.  
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Figure 22: Collagen activates IKK and induces IκBα degradation. A: Expression of 
phosphorylated IκB kinase (p-IKK) after a 2µg/ml collagen stimulation for 7min (n=3). B: Illustrated are 
Western blots of platelet lysates after a 7µg/ml collagen treatment for 15min (col) or 0.5µM ionomycin 
(iono) for 10min (n=6). A preincubation with the specific proteasome inhibitor 1µM epoxomicin (epox) 
for 10min was used in comparison (before adding ionomycin n=5; before adding collagen n=2). 
Degradation of IκBα is indicated. ß-actin is used as a loading control. 
 
As seen in Figure 22A stimulation of 2µg/ml collagen strongly induces 
phosphorylation of the IκB kinase (p-IKK). Expression of NFκB inhibitory protein IκBα 
is decreased in platelets after collagen stimulation compared to resting platelets 
meaning IκBα seems to be degraded in collagen-stimulated platelets. When the 
proteasome is inhibited IκBα degradation upon collagen stimulation seems to be 
prevented.  
Taking all this data in account a connection of the NFκB pathway and the 
proteasome in collagen-induced aggregation of human platelets can be postulated.  
 
3.3 Clinical investigation of mitochondrial function 
and proteolytic processes in platelets during sepsis 
The ubiquitin proteasome system is known to be involved in many diseases because 
it is not only there to degrade proteins for intracellular protein turnover but regulates 
many cellular mechanisms. Proteolysis is essential for nucleated cells and the 
importance of proteolysis in anucleate platelets was also declared [98]. Therefore 
abnormalities of the ubiquitin proteasome system/proteasome can be found in 
diseases but in sepsis the proteasome has not been studied yet. Sepsis is still a 
leading cause of morbidity and mortality and platelet cell death leading to 
thrombocytopenia has been closely associated with it [36, 37, 193]. Apoptosis is a 
cellular process that is mainly regulated by caspases but the proteasome plays an 
important role as well, i.e. degrading pro-survival proteins [194]. Our group was able 
to show that bacteria can directly activate the apoptotic pathway in platelets [36] and 
Tisdale et al. [155] demonstrated that muscle proteolysis during sepsis is dependent 
on the proteasome. Therefore not only quantification of mitochondrial associated 
apoptotic markers in platelets was performed and a correlation of an apoptotic 
marker with the clinical disease severity in sepsis patients during disease course was 
analyzed but involvement of the proteasome during sepsis was also investigated. 
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3.3.1 Markers of platelet apoptosis and mitochondrial control of 
platelet apoptosis 
Functions that traditionally are attributed to nucleated cells have been discovered in 
anucleate platelets as well. Platelets show signs of programmed cell death, called 
apoptosis [48, 49]. Platelet apoptosis is triggered by numerous chemical agents 
(such as the calcium ionophore A23187 [50]) and the intrinsic mitochondria-
dependent pathway with, e.g., depolarization of the mitochondrial membrane 
potential, degradation of the anti-apoptotic protein Bcl-xL, and activation of caspase-
8 is well studied in platelets [36, 54, 56]. For analyzing the mitochondrial integrity in 
human platelets an assay detecting the mitochondrial membrane potential (Mmp) 
was established. It is assessed as a ratio of the mean red and mean green 
fluorescence of triplicates. A decrease in the ratio (Mmp-Index) represents a loss in 
mitochondrial membrane potential, which happens in apoptotic cells. The calcium 
ionophore A23187 that is known to induce cell death at a concentration of 10µM is 
used during this study to stimulate apoptosis. 
 
Figure 23: Depolarization of the mitochondrial membrane potential in human platelets. A: Mmp-
Index was detected by JC-1 staining and flow cytometer analysis. Platelets from healthy donors were 
analyzed and those platelets were compared to apoptosis-induced cells (10µM A23187,A23, for 
10min; Mann-Whitney rank sum test, n=10, *p<0.001). B: Representative flow cytometer 
measurements of one control and of an apoptosis-induced sample (10µM A23187=A23 for 10min) is 
pictured. Mitochondrial membrane depolarization is characterized by a reduction in median red 
fluorescence and an increase in median green fluorescence. 
 
Figure 23 demonstrates the depolarization of the mitochondrial membrane potential 
in human platelets undergoing apoptosis. Apoptotic platelets lose their mitochondrial 
membrane potential shown by a significantly low Mmp-Index (0.14±0.01 versus 
control 1.01±0.04). A representative illustration of the decrease of Mmp-Index 
detected by JC-1 staining and FACS measurements is seen in Figure 23B. The 
control platelet population (circle) shows red fluorescence and the apoptotic platelet 
population (A23187) emits more green fluorescence.  
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3.3.2 Mitochondrial dysfunction of platelets correlates with clinical 
disease severity and outcome in sepsis 
Sepsis is still a leading cause of morbidity and mortality and thrombocytopenia has 
been closely associated with it. Our group was able to show that bacteria can directly 
activate the apoptotic pathway in platelets [36]. Therefore the apoptotic marker, loss 
of mitochondrial membrane potential, was analyzed according to a correlation with 
clinical disease severity in sepsis patients during disease course and if it may be a 
valuable parameter to disease severity and clinical outcome.  
 
Platelet mitochondrial membrane depolarization of sepsis patients correlates 
with clinical disease severity 
First of all it was examined if the severity of sepsis is associated with the Mmp-Index 
of patients. Table 5 indicates the 26 sepsis patients and 17 control patients of our 
study. Sepsis patients were subclassified as severe sepsis (n=17) including septic 
shock and non-severe sepsis (n=9). Table 5 lists the site of infection in studied 
patients, platelet count and clinical disease scores Acute Physiology and Chronic 
Health Evaluation Score II (APACHE II), Sequential Organ Failure Assessment Score 
(SOFA) and Simplified Acute Physiology Score II (SAPS II). There was no statistical 
age difference among the groups. 
 
 Sepsis Severe Sepsis/Septic shock Controls 
Patient number 9 17 17 
male/female 6/3 9/8 10/7 
Age 57 [42 to 71] 69 [55 to 78] 74 [68 to 79] 
Platelet counts 
(x 103/µl) 
198 [161 to 
210] 
98 [79 to 159] 176 [145 to 230] 
 
APACHE II score 9 [8 to 13] 23 [15 to 26]  
SOFA score 0 [0 to 1] 7 [5 to 11]  
SAPS II score 33 [25 to 35] 53 [40 to 58]  
Site of infection   Admission cause 
pulmonary 4 7 cardiac:            3    
urinary 0 2 pulmonary        2 
abdominal 3 5 endocrine         3 
endocarditis 0 1 rheumatic         1 
soft tissue 0 1 GI                     4 
others 2 1 other                 4 
Table 5: Clinical patient characteristics. Numbers are given as median and [interquartile range] 
[37]. 
 
Comparision of Mmp-Index of patients with clinical scores APACHE II, SOFA and 
SAPS II was performed (Figure 24). Mmp of sepsis patients (n=26) correlated 
significantly with clinical disease severity scores (APACHE II: r=-0.867, SOFA: r=-
0.857, SAPS II: r=-0.839). Accordingly lower Mmp-Index (apoptotic cells) are 
paralleled by higher score numbers (more severe disease status). 
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Figure 24: Correlation of platelet mitochondrial membrane potential with clinical scores. Dot 
plot correlation of the individual mean platelet Mmp-Index of each patient calculated from JC-1 
measurements and the clinical disease severity scores APACHE II (A), SOFA (B), SAPS II (C) in 26 
patients with sepsis are shown. Lower Mmp-Index values indicate a loss of mitochondrial membrane 
potential, whereas higher clinical disease scores indicate more severe illness. R = statistical 
correlation coefficient, p<0.0001 denotes statistically significant correlation of values [37]. 
 
Reduction of platelet mitochondrial membrane potential and pro-apoptotic Bcl-
xL in patients with severe sepsis 
To find out the level of apoptosis in patients with sepsis we detected the Mmp-Index 
in patients with severe sepsis (including septic shock), non-severe sepsis (sepsis 
without organ failure) and control patients. To strengthen previous data another 
apoptotic marker, expression of pro-survival protein Bcl-xL, was analyzed. 
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Figure 25: Comparison of platelet mitochondrial membrane potential of patients with sepsis, 
severe sepsis, and control patients. A: Box-and-whisker plots (with its median and lower/upper 
quartile) illustrate platelet Mmp-Index of patients with sepsis (non-severe without organ failure), severe 
sepsis including septic shock and control patients without infection (control n=14). Lower Mmp-Index 
values indicate a loss of mitochondrial membrane potential. (Kruskal-Wallis one-way analysis of 
variance, *p<0.001). B: Platelet Bcl-xL expression in patients with sepsis (lanes 1-3) and severe 
sepsis (lanes 4-7) was compared by immunoblotting. Bcl-xL expression was quantified by band 
densitometry analysis with the help of a Bcl-xL to actin ratio. Mean Bcl-xL to actin ratio for the sepsis 
group was set as 1. Relative Bcl-xL expression between groups based in actin loading is shown. C: 
Flow cytometry analysis of platelets from a patient with severe sepsis, sepsis and a control patient are 
shown. Mitochondrial membrane depolarization is characterized by a decrease in median red 
fluorescence and an increase in median green fluorescence. Adapted from Grundler et al. [37]. 
 
Platelet Mmp-Index is significantly reduced in patients with severe sepsis including 
septic shock compared to patients with sepsis without organ failure (non-severe) or 
control patients as seen in Figure 25A (median severe sepsis 0.18[0.12 to 0.25], 
sepsis 0.78[0.51 to 0.85], control patients 0.89[0.68 to 1.00]). Figure 25B 
demonstrates that the pro-survival protein Bcl-xL is less expressed in platelets of 
patients with severe sepsis (lanes 4 to 7) compared to the expression of patients with 
sepsis (lanes 1 to 3). Representatives of the flow cytometer analysis from each 
patient group are highlighted in Figure 25C, showing clearly the loss of red 
fluorescence and increase of green fluorescence in platelets of patients with severe 
sepsis. 
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Platelet mitochondrial membrane depolarization correlates with clinical disease 
outcome 
Platelet mitochondrial membrane potential had not been investigated in a clinical 
follow-up design neither with regard to sepsis outcome before. Thus Mmp-Index on 
admission and follow-up in the group of sepsis survivors and non-survivors who died 
as a consequence of sepsis was detected.  
 
 
 
Figure 26: Comparison of platelet mitochondrial membrane potential of survivors and non-
survivors of the severe sepsis group. A: Box-and whisker-plots (with its median and lower/upper 
quartile) show platelet Mmp-Index of survivors (n=10) and non-survivors (n=7) of the severe sepsis 
group on admission and during follow-up (control n=17). Lower Mmp-Index values indicate a loss of 
mitochondrial membrane potential. B: Individual Mmp-Index values of sepsis survivors and non-
survivors on admission and during follow-up are shown (Kruskal-Wallis one-way analysis of variance, 
*p<0.001) [37]. 
 
As demonstrated in Figure 26 there was no significant difference in platelet Mmp-
Index between survivors and non-survivors (Mmp-Index on admission of non-
survivors 0.16[0.11 to 0.22], survivors 0.24[0.11 to 0.42]). During clinical course, 
significant recovery of Mmp-Index was observed in the group of survivors (Mmp-
Index on follow-up of survivors 0.90[0.71 to 1.02]), this follow-up Mmp recovered to 
baseline levels of controls (Mmp of control 0.88[0.67 to 1.03]). But the Mmp values of 
non-survivors remained low (Mmp on follow-up of non-survivors 0.27[0.23 to 0.31]), 
that was non significant compared to the Mmp on admission but it is significantly 
reduced compared to the follow-up Mmp of survivors. Illustration of individual Mmp-
values demonstrates the lack of recovery in non-survivors of the severe sepsis group 
which all remained below 0.5 Mmp-Index and the recovery of Mmp-Index values in 
survivors on follow-up (Figure 26B). This Mmp-Index might be a valuable adjunct 
parameter to help in the assessment of disease severity, risk stratification and clinical 
outcome. 
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3.3.3 Patients with severe sepsis show enhanced proteasome 
activity in human platelets 
As demonstrated platelets of sepsis patients undergo signs of apoptosis (Figure 25). 
Since apoptosis is regulated through the proteasome amongst others by degrading 
proteins, such as pro-survival proteins, the platelet proteasome during sepsis was 
further analyzed. Here proteasome activity in platelets of sepsis patients was tested 
and platelets incubated with the pathogenic E. coli strain UTI89 which is known to 
induce Bcl-xL degradation [36] were examined. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Proteasome activity is activated during sepsis. Plotted are individually control patients 
(n=9) and patients with severe sepsis including septic shock (n=6) illustrating platelet proteasome 
activity. The line represents the median.  
 
Severe sepsis patients show a tendency to a higher 20S CT-L activity in platelets 
compared to control patients (median activity: 7.51±1.18FU/µg versus 
4.40±0.52FU/µg, Figure 27). But a larger population should be studied.  
Previous work demonstrated that under physiological conditions regulation of the 26S 
proteasome is more important than the 20S proteasome. Therefore we studied an 
uropathologic E. coli strain that might cause sepsis on its ability to enhance the 26S 
proteasome activity in platelets.  
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Figure 28: Proteasome activity is activated by Escherichia coli UTI89. A: 26S T-L activity of the 
platelet proteasome was analyzed and activity of treated platelets was calculated relative to resting 
platelets after 4h (ctr). Platelets were incubated with 4 x 106 bacteria/ 1 x 108 platelets for 4h. Next to 
the bars showing measured activities line plots indicate the activity from each individual donor (n=6). 
B: Western blot analysis of the proteasome substrate Talin-1 from control platelets after 4h (ctr) or 
UTI89 treated platelets for 4h. Β-actin was used as a loading control (n=3). 
 
UTI89 activates the 26S T-L activity to 3.86±1.66-fold and the strain without its toxins 
does not seem to activate the 26S activity to such a high extend (2.16±0.75, Figure 
28A). The finding that the proteasome substrate Talin-1 is cleaved during an E. coli 
treatment supports this data (Figure 28B). Platelets incubated with UTI89 express 
more cleaved Talin-1 compared to resting platelets.  
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4 Discussion 
 
4.1 Analysis of the proteasome in human platelets  
As one of the major degradation systems the proteasome is an essential 
multicatalytic complex in eukaryotic cells. Since the crystallographic characterization 
of this huge particle we have a better knowledge of its structure but due to its 
complexity its regulation has not fully been understood until today.  
A focus on anucleate platelets and its abilities to perform diverse cellular mechanism 
that were limited to nucleated cells turned up a couple of years ago. In this context 
little is known about the role of the proteasome in platelets although it has been 
identified in platelets. This study provides further evidence of the proteasome in 
platelets, which will be discussed in the following.  
 
4.1.1 Anucleate platelets contain an active proteasome 
The proteasome in anucleate platelets has been discovered earlier [59, 159, 160] 
and recently Klockenbusch et al. published a proteomic analysis of platelets 
identifying nearly all proteasome subunits [63]. Observations of Klockenbusch et al. 
[63] are in accordance with my data showing the expression of three representative 
subunits of the proteasome (Figure 9).  
Furthermore, during this study the chymotrypsin-like (CT-L) activity of the 20S 
proteasome in human platelets was examined (Figure 10). The CT-L activity of the 
20S proteasome was significantly inhibited by epoxomicin and lactacystin. 
Epoxomicin is shown to be the more effective inhibitor which is completely in 
accordance with literature [140]. Other work was able to show an active proteasome 
in platelets as well [159, 160] but up to date there are no measurements of all three 
proteolytic activities, namely the chymotrypsin-like, trypsin-like (T-L), and caspase-
like (C-L) activities, of the 20S and 26S proteasomes. Figure 12 demonstrates that 
the CT-L, T-L and C-L activities of the 20S and 26S proteasome are detectable in 
human platelets. The 26S proteasome is considered more physiologically important 
than the 20S proteasome due to its role in degrading the majority of proteins. The 
role of the 20S core proteasome alone is not clear until today. A conformational 
change of the 20S proteasome is needed to let proteins/peptides enter its cavity 
[125] and this conformational change is physiologically only initiated through its 
regulators [125]. Furthermore, the 26S proteasome was differentially regulated by 
calcium ionophores (Figure 15) and collagen (Figure 16) whereas the 20S 
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proteasome hardly responded to those substances. This underlines the higher 
physiological role of the 26S proteasome.  
Thus, the analysis presented (Figure 12) of all three activities of the 20S and 26S 
proteasome is a significant contribution providing a physiologically active proteasome 
in human platelets.  
 
4.1.2 The proteasome is differentially regulated in human platelets 
There are only few studies investigating the proteasome activity in platelets [159, 
160, 163] and only few proteasome inhibitors were analyzed. This study 
demonstrates that established proteasome inhibitors epoxomicin, bortezomib and 
lactacystin restrain all catalytic proteasome activities in platelets (Figure 10 and 
Figure 14). The CT-L, T-L, and C-L activities of the 20S and 26S proteasome were 
inhibited to different extents (Figure 14). It is known that there are different inhibitory 
concentrations for those proteasome inhibitors. Here, Epoxomicin was found to be a 
more potent inhibitor for the CT-L and C-L activities than lactacystin which is in 
accordance with Meng et al. who detected a 4-fold faster inactivation rate of 
epoxomicin compared to lactacystin for the CT-L activity of the 20S proteasome, 
whereas the T-L activity was nearly identical [140]. Additionally, bortezomib hardly 
inhibited the T-L acitivities of the proteasome (Figure 14). This is demonstrated by 
various other groups as well [136, 137] and Groll et al. discovered that bortezomib 
has different binding affinities to the catalytic sites due to individual side chains of the 
inhibitor that interact distinctly with protein specificity pockets [137]. 
Nayak et al. were the first to describe a proteasome regulation upon chemical 
stimulation [163]. They treated platelets with a calcium ionophore and detected an 
increase of the 20S CT-L activity. The data communicated here show a regulation of 
the more physiological 26S proteasome for the first time (Figure 15 and Figure 16). A 
proteasome activity enhancement by calcium ionophors was measured in this context 
and the higher impact was observed for the 26S proteasome compared to the 20S 
proteasome (Figure 15). With their protocol Nayak et al. might have measured only 
the 20S proteasome activities and not the 26S proteasome activities and therefore 
only detected the activity enrichment in the 20S proteasome. Because the 26S 
proteasome is more relevant in vivo, it might be hypothesized that the proteasome in 
vivo in platelets is highly regulated by external factors. 
Accordingly, Figure 16 illustrates a 26S CT-L proteasome activity increase for the 
platelet agonist collagen. Collagen is an established agonist for platelet aggregation, 
a fundamental function of platelets (see section 1.1.2). The observation that a platelet 
agonist is able to regulate proteasome activity emphasizes the significance of the 
proteasome in platelets for performing cellular mechanism. It needs to be considered 
that the proteasome plays a role in activation pathways of platelets.  
Analysis of all catalytic activities of the 20S and 26S proteasome and especially the 
functionality of the proteasome in platelets, demonstrated by its ability to be 
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regulated, shows the importance of the platelet proteasome and its possible influence 
in cellular mechanisms.  
4.1.3 Proteasome substrates 
Through a comprehensive analysis of peptides bound to MHC I and processed by 
proteasome complexes cytoskeletal proteins such as Filamin A and Talin-1 were 
identified as proteasome substrates (Table 4 and Figure 17). The proteins Filamin A 
and Talin-1 have also been found by others to be proteasome substrates during the 
course of this study [150]. Cytoskeletal proteins are essential for the shape change of 
platelets upon activation and indeed, more than 50% of the platelets’ total protein 
belong to the cytoskeleton. Cleaved Filamin A and Talin-1 fragments were found 
higher expressed when the proteasome activity was enhanced and preincubation 
with epoxomicin depresses the cleavage of the proteasome substrates Filamin A and 
Talin-1 (Figure 17). Those facts are an indication that the proteasome is involved in 
pathways that modify the cytoskeleton. 
The data of Filamin A and Talin-1 presented here (Figure 17) suggest a novel 
function of proteasomes. Already in 2002 Rape discussed models of a novel 
mechanisms that might yield biologically active protein fragments [151]. The 
proteasome might not only degrade proteins but also cleave them into protein 
fragments. In nucleated cells proteins, such as the transcription factor NFκB are 
generated by the proteasome in that fashion [147-149]. It might be speculated that 
Filamin A and Talin-1 are proteins, which are processed into still active protein 
fragments in human platelets. This highlights the already suggested novel function of 
proteasomes.  
In conclusion, cytoskeletal components were identified as proteasome substrates 
what demonstrates an impact of the proteasome on the cytoskeletal modifications.  
 
4.2 Function of proteasomes in anucleate platelets 
Not only the understanding of a protein structure and its active sites is crucial but the 
role of this protein or its purpose leads to the better knowledge of platelet biology. 
Protein degradation in anucleate platelets is an important system, which does not 
only degrade intracellular proteins for protein turnover but also regulates important 
cellular processes [98]. Yet how many and which proteins are degraded by the 
proteasome in platelets has not been analyzed until today.  
Only when platelets were identified as antigen presenting cells [60] and since they 
contain the proteasome machinery [63], it was suggested that as in nucleated cells 
the proteasome (the immunoproteasome) has the role of processing antigens for 
antigen presentation on MHC I complexes. It is therefore very likely that the 
proteasome is involved in regulation of additional cellular mechanisms in platelets.  
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4.2.1 The proteasome affects platelet aggregation 
In this study it was demonstrated that the proteasome affects platelet aggregation 
particularly in a collagen-induced aggregation pathway (Figure 18). During the course 
of this study Gupta et al. indicated a cellular process in platelets that depends on the 
proteasome [150]. They published data proposing an involvement of the proteasome 
in platelet activation. This is completely in accordance with data shown here, stating 
that proteasome inhibitors impair platelet aggregation (Figure 18). Gupta et al. stated 
that low concentrations of thrombin reduced aggregation and thrombin and ADP 
stimulation suppressed microparticle shedding. They demonstrated that Filamin A 
and Talin-1 are ubiquitinated and then cleaved by the proteasome in platelets. This 
let them to hypothesize that the platelet proteasome modifies cytoskeletal proteins 
and promotes platelet activation.  
My data shows that aggregation induced by ADP is reduced when platelets are 
treated with proteasome inhibitors (Figure 18). Further findings propose that 
aggregation induced by low concentrations of collagen also weakens aggregation 
(Figure 18). This suggests that the proteasome is regulated by the platelet agonist 
collagen (Figure 16) and it can be concluded that the platelet proteasome modifies 
cytoskeletal proteins Filamin A and Talin-1 in this context (Figure 17).  
This is supported by an observation of platelet concentrates, that show a reduction in 
their ability to aggregate over time (Figure 11) [195, 196] and they demonstrate a loss 
of proteasome activity as well (Figure 11).  
Collagen, as stated here, activates the proteasome activity and then leads to 
aggregation (Figure 16 and Figure 18). Illustrated in this study is the function of the 
proteasome in platelet aggregation. However, the underlying signaling pathways 
have not been described yet. The next section will discuss a signaling pathway 
involving the platelet proteasome.  
 
4.2.2 NFκB a regulator of the proteasome in platelets 
NFκB is a known transcription factor in nucleated eukaryotic cells and it was shown 
to exist in anucleate platelets as well [69, 70, 79]. NFκB is not the only transcription 
factor discovered in anucleate platelets [64-68] and furthermore NFκB was 
demonstrated to influence platelet biology through a non-genomic function. Malaver 
et al. were the first to suggest this non-genomic function of NFκB in platelets [70]. 
They published amongst other results a reduction of aggregation by NFκB inhibitor 
treatment. Other groups confirmed functional NFκB in platelets [79, 80]. In 
accordance with this data, Figure 19 indicates a decrease of ADP- and collagen-
stimulated aggregation by NFκB inhibitors. NFκB mediates aggregation in platelets 
similar to what is shown for the proteasome in Figure 18. This finding led to the 
assumption that NFκB inhibitors might reduce the collagen-induced proteasome 
activity induction similar to proteasome inhibitors. Figure 20 illustrates that NFκB 
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inhibitors reverse the proteasome activity increase with collagen. The 26S CT-L 
activity of the proteasome is increased by collagen but after a preincubation with 
NFκB inhibitors, Ro 106-9920 and Bay 11-7082, collagen did not result in an 
enhancement of the proteaome activity (Figure 20). Therefore inhibition of NFκB 
must reflect to proteasome activity and is connected to the collagen pathway. 
Additionally, Figure 21 indicates an activation of NFκB activity in human platelets by 
collagen. NFκB is activated upon degradation of its inhibitor IκBα and subsequent 
release of its nuclear localization signals (NLS). Those freed NLS or the NFκB’s 
response element can be detected even though non-genomic activity of NFκB is 
predicted. Gambaryan et al. measured NFκB activity in platelets in the same way and 
observed activation of the NFκB activity with another platelet agonist [80]. While they 
treated platelets with low concentrations of thrombin, evidence for an induction of 
NFκB activity upon treatment with low concentrations of collagen is provided in this 
study (Figure 21). As expected, the NFκB inhibitor Bay effectively inhibited the 
detected NFκB activity (Figure 21) and was therefore used as a negative control. 
Moreover, a reduction of NFκB activity by proteasome inhibitors might be expected 
as this was already shown in HeLa cells for epoxomicin [140]. The reduction of NFκB 
activity found in this study was only moderate (Figure 21) due to a relative small 
amount of replicates.  
To study another read-out for proteasome activity the established proteasome 
substrate Talin-1 was tested. The full-length protein of the proteasome substrate 
Talin-1 is increasingly cleaved in platelets stimulated with collagen compared to 
resting platelets (Figure 21B). The cleaved fragment of Talin-1 is found at a higher 
expression level in collagen-stimulated platelets. This might result from the increased 
proteasome activity after stimulation of collagen. When proteasome activity 
enrichment is decreased by NFκB inhibitors, more full-length Talin-1 than cleaved 
Talin-1 is measured (Figure 21B). The change of these ratios indicates a connection 
of the NFκB pathway and the proteasome.  
Subsequently, to further support an initiation of the NFκB pathway in platelets under 
collagen stimulation, activation of the IκB kinase (IKK), the activator of the NFκB 
pathway, was measured by assessing its phosphorylation state. IKK is 
phosphorylated when platelets are treated with collagen (Figure 22A) which has also 
previously been shown [83, 84].  
Another important mode of NFκB regulation is through the degradation of the 
inhibitory protein of NFκB, IκBα. Figure 22B indicates a degradation of IκBα after 
stimulating platelets with collagen. In return, inhibition of the proteasome prevents 
IκBα degradation. In 2010 there was data published showing that IκBα is degraded 
and the NFκB pathway is activated when platelets are treated with thrombin, another 
platelet agonist [70, 80]. Figure 22B demonstrating the degradation of IκBα in the 
collagen pathway for the first time is an additional hint that the NFκB pathway is 
activated during platelet activation. 
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Taken together, an activation of the NFκB activity, phosphorylation of the IKK, and 
degradation of IκBα was observed in platelets in response to collagen stimulation. An 
activation of the NFκB pathway in activated platelets seems reasonable.  
More importantly a potential connection of NFκB and the proteasome in collagen-
stimulated platelets is implied (Figure 20 and Figure 21B). Not only is a collagen-
induced proteasome activity enhancement prevented by NFκB inhibitors, but an 
increased cleavage of the proteasome substrate Talin-1 is also prevented by NFκB 
inhibitors. An inhibition of IKK by Bay does not show a collagen-induced 
enhancement of proteasome activity and reduces aggregation. The following picture 
summarizes the proposed activation pathway in platelets that connects NFκB and the 
proteasome (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Hypothetical pathway of collagen-induced aggregation involving NFκB and the 
proteasome. Collagen stimulation leads to phosphorylation of IKK which further phosphorylates IκBα. 
This inhibitory protein is then degraded by the proteasome to transfer NFκB in an active state. 
Inhibition of IKK reduces NFκB activity and aggregation. As a side effect inhibition of IKK also restrains 
proteasome activity. An inhibition of the proteasome was shown to lower the ability of platelets to 
aggregate. In return, when the proteasome is inhibited, it no longer degrades the inhibitory IκBα 
protein of NFκB. The resulting inactivation of NFκB also reduces aggregation. Bay: Bay 11-7082, Ro: 
Ro 106-9920, Epox: epoxomicin, ECM: extracellular matrix, ICF: intracellular fluid 
 
This pathway is a novel and significant contribution in understanding the platelet 
biology, proposing the involvement of the proteasome in platelet activation and 
stating a non-genomic role of NFκB in platelets. NFκB is involved in platelet 
activation by regulating the proteasome.  
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Further mechanisms for non-genomic functions of NFκB or more extended platelet 
pathways being regulated by the proteasome remain to be established. One must 
also keep in mind that NFκB inhibitors used here are not selectively inhibiting the 
NFκB pathway and other pathways in platelets might be affected to some extent [87]. 
Yet, more and more work on non-genomic functions of NFκB in platelet activation is 
being published regularly [82, 84-86]. NFκB might not only play a role in platelet 
activation and aggregation but also in granule secretion [82]. As mentioned in section 
1.3.5, there has even been a study on IKK and its role in platelet secretion [85]. All 
these publications and performed experiments in this study with the identified novel 
pathway contribute to this functional aspect of the proteasome and NFκB in platelet 
biology. Platelet activation might start intracellular signaling by enhancing the 
proteasome activity and subsequently activating the NFκB pathway.  
Collectively, inductors of platelet aggregation such as collagen activate both the 
proteasome and the NFκB pathway which are connected and mutually influence its 
activity on a molecular basis. Therefore inhibitors that affect the proteasome or the 
NFκB pathway also change the capacity of platelets to aggregate.  
 
4.3 Sepsis as one of many clinical perspectives 
The proteasome is one of two major degradation systems in nucleated cells and 
proteolysis is not only crucial for the total protein turnover but regulates important 
cellular processes, such as cell cycle, division, survival, oncogenesis, transcription, 
development, selective elimination of abnormal proteins, and antigen processing 
[101-104]. The importance of the proteasome as initiator of degradation has also 
been implied in anucleate platelets [98].  
Previous work discovered that the proteasome can affect platelet vitality and 
apoptosis. Bacteria-induced apoptosis in platelets was shown [36]. Therefore 
analysis of platelets in a clinical setting was investigated. Since apoptosis is one of 
many cellular processes regulated by the proteasome (for instance, through 
degrading pro-survival proteins) [194] an involvement of the plateletal proteasome in 
sepsis was tested. It was already shown that proteolysis in smooth muscle cells of 
sepsis patients is depending on the proteasome [155, 197].  
 
4.3.1 The mitochondrial membrane potential in platelets as a marker 
of sepsis 
Sepsis is still a leading cause of morbidity and mortality and the link of 
thrombocytopenia as a predictor of clinical prognosis in sepsis patients has been well 
established, although investigations on a molecular level are still rare [193]. Some 
recent work states that bacteria isolated from sepsis patients directly activate the 
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apoptotic pathway in platelets [36] and other groups have described that bacterial 
factors of S. aureus induce mitochondrial membrane depolarization and apoptosis in 
platelets [198]. Thus, it is tempting to speculate that the loss of platelets in sepsis 
patients is a result of bacterial action or the septic milieu.  
As shown in Figure 24 and Figure 25 the platelet mitochondrial membrane 
depolarization and decrease of pro-survival proteins correlate with clinical disease 
severity in patients with sepsis. This affirms previous work where the mitochondrial 
membrane depolarization also correlated with disease severity of a diverse group of 
sepsis patients [199]. However, this study is the first to demonstrate that the degree 
of platelet mitochondrial membrane depolarization correlates with disease severity 
during the disease course and outcome (Figure 26). Platelet mitochondrial 
membrane depolarization in a subgroup of patients with severe sepsis was compared 
on admission to a control group and they were compared during clinical disease 
course. Mmp-Index during disease course was studied in survivors and non-
survivors. On admission, initial Mmp-Index values were significantly decreased but 
the patients who survived sepsis showed recovery of Mmp-Index on follow-up (Figure 
26).  
To conclude, mitochondrial membrane depolarization in platelets correlates with 
clinical disease severity in patients with sepsis during the disease course and may be 
a valuable adjunct parameter to aid in the assessment of disease severity, risk 
stratification, and clinical outcome. Results from this study and previous 
investigations seem to promise that markers of platelet apoptosis may assist in the 
evaluation of sepsis in the future.  
 
4.3.2 Proteasome activity is enhanced in platelets during sepsis 
This study emphasizes the event of apoptosis in platelets during sepsis. Apoptosis is 
one of many cellular processes regulated by the proteasome. Even though apoptosis 
is controlled through various caspases the proteasome degrades involved proteins, 
such as pro-survival proteins [194]. Bcl-xL protein degradation is increased when 
platelets are treated with pathogenic E. coli [36]. Hence, the involvement of the 
plateletal proteasome in sepsis should be investigated. It is already said that 
proteolysis in sepsis patients is depending on the proteasome [197] and this data 
was confirmed with a more detailed analysis on smooth muscle cells of sepsis 
patients [155].  
Figure 27 indicates that the proteasome activity in platelets of sepsis patients might 
be enhanced. It is tempting to assume that platelets increase their proteasome 
activity and subsequently apoptosis is induced. Another indication might be the rising 
proteasome activity in platelets that were in vitro incubated with uropathogenic E. coli 
bacteria. Figure 28 illustrates a bacteria-induced enhancement of proteasome activity 
in platelets. In accordance with this, data exist demonstrating that lipopoly-
saccharides (LPS), a membrane component of gram-negative bacteria, are able to 
Katharina Gründler  4 Discussion 
74 
 
activate the proteasome activity [200]. Moreover, this study discusses that the 
proteasome substrate Talin-1 is cleaved more under a proteasome activity induction 
performed by calcium ionophores or collagen (Figure 17). Platelets treated with 
bacteria contain also more of the cleaved Talin-1 fragment. The full-length protein is 
found higher expressed in resting platelets than in bacteria incubated platelets 
(Figure 28B) suggesting an increased proteasome activity in bacteria treated 
platelets.  
Those experiments are only preliminary. A larger study population should be 
analyzed according to their proteasome activity and the mechanism for an inclining 
proteasome activity during apoptosis should be clarified. Nevertheless, these findings 
argue an influence of the proteasome in platelets during sepsis. The proteasome 
plays an important role in many diseases and in platelets it is associated with the 
activation pathway. Here, data is provided suggesting a relevance of proteolysis in 
platelets during sepsis. This data is supported by a study by Qureshi et al. proposing 
the proteasome as an important target in gram-negative sepsis [200].  
 
4.4 Conclusion and Outlook 
This study confirms the existence of a functional 20S and 26S proteasome in human 
platelets and provides data that emphasize its significance in platelet biology.  
Presented is a possible novel pathway during platelet activation that mutually 
connects the platelet proteasome during platelet activation with a non-genomic 
function of NFκB in platelets. Platelet activation might induce intracellular signaling by 
initiating the NFκB pathway that mediates proteasome activity. A better 
understanding of platelet biology and the exact role of the proteasome in platelets 
may offer the possibility to monitor side-effects of proteasome inhibitors on platelets 
but also study proteasome related disease processes that result from platelets. 
 
This work further contributes data that illustrate how markers of mitochondrial 
function and proteasome activity could aid in the assessment of the disease severity 
and disease course of patients with sepsis.  
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Abbreviations 
°C  Degree Celsius   
AA  Arachidonic acid   
ADP  Adenosine diphosphate   
AMC  7-amino-4-methylcoumarin   
AML  Acute myeloid leukemia   
APACHE  Acute Physiology and Chronic Health Evaluation   
APS  Ammonium persulfate   
ATP  Adenosine triphosphate   
AU  Arbitrary unit   
Bay  Bay 11-7082   
BCA  Bicinchoninic acid   
borte  Bortezomib   
BSA  Bovine serum albumin   
CD  Cluster of differentiation   
CID  Collision induced dissociation   
CKII  Casein kinase II   
C-L  Caspase-like   
clm  Chloramphenicol   
cnf1  cytotoxic necrotizing factor 1   
col  Collagen   
CT-L  Chymotrypsin-like   
ctr  Control   
DAG  Diacylglycerol   
DMEM  Dulbecco’s Modified Eagle Medium   
DMSO  Dimethyl sulfoxide   
ds  Double stranded   
DTT  Dithiothreitol   
E. coli  Escherichia coli   
e.g.  Exempli gratia   
ECM  Extracellular matrix   
EDTA  Ethylenediaminetetraacetic acid   
ELISA  enzyme-linked immunosorbent assay   
epox  Epoxomicin   
et al.  And others (et alii)   
FACS  Fluorescnece activated cell sorter   
FCS  Fetal calf serum   
FU  Fluorescence units   
g  Acceleration due to gravity   
GP  Glycoprotein   
GR  Glucocorticoid receptor   
h  Hour   
HEPES  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid   
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HLA  Human leukocyte antigen   
hlyA  α-hemolysin   
HMEC  Human microvascular endothelial cells   
HRP  Horseradish peroxidase   
ICF  Intracellular fluid   
IKK  IκB kinase   
IP3  1,4,5-triphosphate   
ITAM  Immunoreceptor tyrosine-based activation motif   
JC-1  Tetrachlorotetraethylbenzimidazolylcarbocyanine iodide   
kan  Kanamycin   
lacta  Lactacystin   
LPS  Lipopolysaccharides   
MC  Monoclonal   
MHC I  Major histocompatibility complex class I   
min  Minutes   
Mmp  Mitochondrial membrane potential   
NFκB  Nuclear factor kappa-light-chain-enhancer of activated B cells   
NLS  Nuclear localization sequence   
p-  phosphorylated   
PAGE  Polyacrylamid gel electrophoresis   
PAR  Protease-activated-receptor   
PBS  Phosphate buffered saline   
PC  Polyclonal   
pH  pH value (potentia hydrogenii)   
PI3K  Phosphatidylinositol 3-kinase   
plt  Platelets   
PMSF  Phenylmethanesulfonylfluoride   
PND  Z-Pro-Nle-Asp-CHO   
PPAR  Peroxisome proliferator activated receptor   
PRP  Platelet rich plasma   
PVDF  Polyvinlylidene difluoride membrane   
Ro  Ro 106-9920   
rpm  Revolutions per minute   
Rpt  Regulatory particle ATPases   
RT  Room temperature   
RXR  Retinoid X receptor   
S. aureus  Staphylococcus aureus   
SAPS  Simplified Acute Physiology Score   
SDS  sodium dodecyl sulfate   
SOFA  Sequential Organ Failure Assessment    
TAP  Transporter associated with antigen processing   
TEMED  Tetramethylethylenediamine   
T-L  Trypsin-like   
TMB  3,3’,5,5’-tetramethylbenzidine   
TP  Thromboxane receptor   
TRAP  Thrombin receptor-activating peptide   
TXA2  Thromboxane A2   
Ub  Ubiquitin   
USA  United States of America   
WB  Whole blood   
wb  Western blot   
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